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Cover image: merged immunofluorescence image of a metaphase 
U2OS osteosarcoma human cell stained for Aurora-A (red) and 
TPX2 (green). Chromosomes are in blue. 
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SUMMARY 
 
Faithful segregation of the replicated genome in mitosis is 
orchestrated by the mitotic spindle: mis-assembly or mis-function 
of the spindle can yield aneuploidy and cell transformation. Mitotic 
regulators are often abnormally expressed in cancer cells and are 
considered attractive targets in anti-cancer therapy. Specific 
inhibitors are being developed, some of which are under clinical 
evaluation. Aurora-A, a mitotic centrosomal kinase regulating 
several aspects of spindle assembly, is overexpressed in many 
tumor types. 
In our laboratory we had previously investigated the role of 
Aurora-A in spindle pole formation, finding that Aurora-A 
inactivation by RNA interference (RNAi) induces the appearance 
of multipolar spindles, characterised by fragmentation of 
centrosomes. We also found that Aurora-A regulates the 
localisation of ch-TOG (colonic and hepatic tumor over-expressed 
gene) and MCAK (mitotic centromere associated kinesin) 
[respectively, a microtubule (MT) stabilizer and a microtubule-
depolymerising kinesin] at spindle poles: in Aurora-A depleted 
cells we observed an abnormal accumulation of ch-TOG, and the 
decrease of MCAK, at spindle poles (De Luca et al., 2008).  
To follow up my interest in the mechanisms of centrosome control 
by Aurora-A I decided to take a PhD project with the aim to 
investigate the underlying molecular mechanisms, and their 
potential relevance in tumorigenesis and cancer therapy.  
I have shown a correlation between mitotic spindle pole 
fragmentation induced by Aurora-A inactivation and 
hyperstabilisation of spindle MTs. Co-silencing of ch-TOG 
prevents spindle pole fragmentation caused by inactivation of 
Aurora-A alone and concomitantly reduces the hyperstabilisation 
of MTs. Furthermore, inhibition of the Eg5 kinesin using 
monastrol (MON) (which decreases pole-directed spindle forces), 
or RNAi against the kinetochore (KT) protein Nuf2 (which 
destabilises MT-KT attachments), also prevent pole fragmentation 
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in Aurora-A-inactivated mitoses. In this part of my project, 
therefore, I have shown that MT-generated forces are unbalanced 
in Aurora-A-inactivated cells and exert an abnormal pressure 
towards spindle poles, ultimately causing centrosome 
fragmentation (Asteriti et al., 2011). These results identify a novel 
function of Aurora-A but also raise concern about the proposed use 
of Aurora-A inhibitors in anti-cancer therapies.  
I have therefore undertaken a comparison between Aurora-A 
inactivation by RNAi and by the specific Aurora-A inhibitor 
MLN8237 in human U2OS osteosarcoma cells. I used both high-
resolution and quantitative microscopy with fixed samples and 
medium- and high-throughput time-lapse microscopy to study the 
effects of MLN8237 treatment at the single cell level. Results 
confirm and extend previous observations on Aurora-A 
inactivation: MLN8237 treatment impairs mitotic entry, induces 
prometaphase (PM) delay and formation of spindles disorganised 
or with additional poles, in a dose-dependent manner. In addition, I 
identified novel phenotypes, suggestive of poorly explored Aurora-
A roles: cells without MTs that display only little asters or spots of 
tubulin, and cells that divide in a mis-oriented manner; at high 
concentrations of MLN8237, I observed the absence of 
chromosome segregation and the re-adhesion into one single cell. I 
never observed death from mitosis and analysis of interphase cells 
originating from MLN8237-treated mitoses reveals DNA 
abnormalities with dose-dependent severity, and hence aneuploidy 
induction. It has recently emerged that the extent of aneuploidy can 
determine subtle genetic instability (tumorigenic) or massive cell 
death: further studies will therefore be needed to predict the 
cellular contexts where Aurora-A inhibition in cancer therapy may 
prove successful.  
In parallel work, I have studied Aurora-A in complex with its 
major regulator TPX2 (Targeting Protein for Xklp2). I have 
contributed to characterise a novel mechanism by which TPX2 
regulates Aurora-A protein stability by protecting Aurora-A from 
protesome-dependent degradation (Giubettini et al., 2011). Based 
Italia Anna Asteriti 
                                                                                                       Pag 12  
on these observations I have carried out literature and data-mining 
searches to assess the oncogenic potential of TPX2 or of the 
Aurora-A/TPX2 complex. I have found that TPX2 is 
overexpressed in many tumors and, moreover, it is frequently co-
overexpressed with Aurora-A. I therefore propose that the 
association between Aurora-A and TPX2 generates a functional 
complex with oncogenic properties and that some roles that are 
conventionally attributed to Aurora-A in cell transformation and 
tumorigenesis are in fact a consequence of the oncogenic activation 
of this complex (Asteriti et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dottorato di ricerca in Genetica e Biologia Molecolare 
 Pag. 13  
INTRODUCTION 
 
1. Mitotic spindle assembly in mammalian cells 
Mitosis is the phase of the cell cycle in which replicated molecules 
of DNA, compacted into chromosomes, are distributed in the two 
daughter cells. This distribution must be equal and precise: the 
consequences of one single error can generate aneuploid cells, with 
unbalanced chromosome sets, that can in turn become the first step 
of cancerous transformation.  
A bipolar spindle is assembled during mitosis in order to ensure 
balanced chromosome segregation (Figure 1A). The mitotic 
spindle is a dynamic, complex macromolecular machine made of 
MTs, polymers of alpha and beta tubulin. In animal cells spindle 
MTs are mainly nucleated from centrosomes (Doxsey, 2001), also 
called MT organising centers, but evidence have emerged that 
mitotic spindles assemble through a cooperative mechanism, in 
which chromatin-mediated pathways of MT nucleation and capture 
also play major roles (O’Connell and Khodjakov, 2007).  
Centrosomes are the only non-membranous organelles in 
vertebrate cells and are composed of two centrioles and 
surrounding pericentriolar material (PCM), which is the site of MT 
nucleation (Doxsey, 2001; Mardin and Schiebel, 2012). At mitosis, 
duplicated centrosomes organise the spindle poles; MTs between 
spindle poles are organised into an antiparallel array, and MTs 
directed towards the cortex form two radial asters (Figure 1B). 
MTs undergo periods of polymerisation and depolymerisation and 
interconvert randomly between these states, a property known as 
“dynamic instability”. MTs are intrinsically “polarised” and are 
organised so that most of the less dynamic and anchored MT 
“minus” ends are near the poles of the spindle, whereas the more 
dynamic and quickly growing “plus” ends extend towards the 
spindle equator or the cell cortex  (Figure 1) (Walczak et al., 2010).   
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Figure 1. Spindle assembly and dynamics. A) Mitotic stages. At 
prophase, chromosomes condensate, centrosomes separate and the 
nuclear envelope breaks down. Chromosomes, captured by MTs in PM, 
align at metaphase, move apart in anaphase and segregate in the re-
forming daughter nuclei at telophase. B) The mitotic spindle. MT minus 
ends are at spindle poles, while plus ends extend towards the cell cortex 
(astral MTs) or KTs; KT fibers contact chromosomes, while interpolar 
MTs form an overlapping antiparallel array, ensuring spindle stability. 
A.!
B.!
modified from Gadde and Heald, 2004!
Telophase  
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The establishment of a proper spindle geometry and bipolar 
organisation requires a regulated balance between opposite 
directional forces exerted along growing MTs (Kapoor et al., 2000; 
Sharp et al., 2000; Tanembaum et al., 2008). Given that improperly 
assembled or multipolar spindles can drive chromosome mis-
segregation, there is a growing research focus on the mechanisms 
through which this balance is generated. 
 
1.1. Microtubule-associated forces and motor proteins  
Mechanical forces are involved in the separation of the two 
duplicated centrosomes and in the organisation of a bipolar 
spindle. There are two types of active spindle-associated forces 
created by polymerisation dynamics and motor proteins and two 
types of passive spindle forces generated by elasticity and friction 
of the MTs (Dumont and Mitchison, 2009). 
The most important forces involved in spindle assembly are the 
active forces. One of the generators of active forces is represented 
by the dynamic properties of the MTs. The concept that spindle 
fibers could push by polymerising and pull by depolimerysing was 
proposed in yeast in 1967 (Inouè and Sato, 1967). These forces are 
not dominant in larger mammalian cells, where the key generators 
of forces on MTs during spindle formation are motor proteins. 
Motors convert energy released by ATP hydrolysis into movement 
along MTs. They move towards the fast growing plus ends (plus 
end-directed kinesins) or towards the relatively stable minus ends 
(minus-end directed dyneins) (Figure 2), directing the transport of 
associated cargoes. Motors can also act as dynamic cross-linkers, 
moving MTs relative to each other: this generates a “sliding-
filament” mechanism that importantly contributes to the 
organisation of MTs during spindle assembly. It is driven 
predominantly by members of the plus-end tetrameric kinesin-5 
family of MT motors: among these, Eg5 has a prominent role 
(Gatlin and Bloom, 2010) (Figure 3). The tetrameric structure of 
Eg5 makes it a particularly attractive candidate for binding 
antiparallel MTs and sliding them apart; its activity in sliding anti-
Italia Anna Asteriti 
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parallel MTs is linked to both the establishment of bipolarity and 
the regulation of steady-state spindle length. The selective 
inhibition or pertubation of Eg5 significantly affects spindle 
assembly: it prevents centrosome separation, resulting in the 
formation of monopolar spindles (Blangy et al., 1995; Kapoor et 
al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Motor proteins organise the mitotic spindle. Plus- (red) and 
minus (yellow) -end directed motors increase or decrease the overlap of 
antiparallel MTs, thus contributing to spindle pole separation. Dynein 
(dark green) at the cortex can pull on astral MTs or focus MT minus-ends 
into poles. Chromokinesins (light green) mediate chromosome 
attachment and movement along MTs.   
 
 
 
 
modified from Gadde and Heald, 2004 
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Figure 3. The Eg5 motor protein. Eg5, in red, has a tetrameric structure 
that allows it to bind antiparallel MTs and slide them apart. By this 
sliding mechanism, Eg5 contributes to establish the spindle bipolarity 
and  regulates steady-state spindle length. 
 
 
Some spindle forces are also associated to chromosomes: 
chromokinesins, which bind both MTs and chromosome arms, and 
KT motors (see Figure 2), such as dynein and CENP-E 
(centromere associated protein E), importantly contribute to move 
chromosomes along the spindle and therefore to chromosome 
congression. By regulating MT plus-end dynamics they determine 
a push of MT minus-ends toward the poles and in this way they 
also contribute to the spindle organisation (rev. in Mazmudar and 
Misteli, 2005; Mao et al., 2010). 
Recently, the role in spindle formation of KT pushing forces, 
already observed early in 1996 by Waters and collegues (Waters et 
al., 1996), is being clarified. KTs are macromolecular complexes 
modified from Gadde and Heald, 2004 
 
Eg5 
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assembled at the centromeric regions of chromosomes, and are 
responsible for the interaction with MTs; the NDC80 complex 
(formed by four proteins: Ndc80, Nuf2, Spc24 and Spc25), 
harbouring both MT- and KT-binding sites, plays a key role in 
establishing KT/MT binding (Figure 4; Santaguida and Musacchio, 
2009).  
 
 
 
   
 
 
 
 
   
 
 
 
 
 
 
  
 
 
  
  
   
 
 
Figure 4. The KT/MT attachment. Left: during mitosis, KTs (yellow) 
assemble on centromeric chromatin and create a contact with MTs 
(green).  KT components required for MT binding are represented on the 
right. The NDC80 complex is a tetramer. The Spc24 and Spc25 subunits 
interact with the MIS12-C, that is a component of the KT, whereas the 
Hec1 (Highly Expressed in Cancer protein 1)/Ndc80 and Nuf2 subunits 
face the MT.    
  
 
 
 
 
 
 
 
modified from DeLuca and Musacchio, 2012 
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Recent studies demonstrated that KTs promote centrosome 
separation after nuclear envelope breakdown by exerting a pushing 
force through the KT fibers (K-fibers), bundles of MTs connected 
to the KTs. This force is generated by the incorporation of tubulin 
subunits at the plus ends of kinetochore MTs and becomes 
essential when other factors (for example Aurora-A) that are 
involved in centrosome separation are altered (Toso et al., 2009; 
Mchedlishvili et al., 2012).  
 
1.2. Non-motor proteins associated to the mitotic spindle   
The organisation of MTs into the highly ordered bipolar mitotic 
spindle depends on the activities of motor proteins (see previous 
paragraph) but also on the action of non-motor MT-associated 
proteins, that are mostly involved in structural organisation 
(Manning and Compton, 2008). 
Among non-motor proteins, microtubule associated proteins 
(MAPs) have a central role in the formation and maintenance of 
the mitotic spindle, through different mechanisms including the 
nucleation and organisation of MTs; they also act by mechanically 
crosslinking MTs, thus providing structural support for the mitotic 
spindle (Manning and Compton, 2008). NuMA (nuclear mitotic 
apparatus protein) and TPX2 are two non-motor proteins that bind 
MTs and are able to crosslink them at the level of centrosomes, 
thus ensuring focusing and integrity of the spindle poles. 
Perturbation of NuMA or TPX2 function results in poorly focused 
spindle poles leading to multipolar spindles (Compton and Luo, 
1995; Garret et al., 2002; Haren et al., 2009). The MT crosslinking 
activity of NuMA is dominant to that of TPX2, but TPX2 becomes 
essential for spindle pole organisation under conditions where 
NuMA function is perturbed (Manning and Compton, 2007).  
Many non-motor proteins also control the density of MTs by 
regulating MT nucleation and/or stability; an example of this class 
of factors is ch-TOG that promotes the assembly of MTs by 
ushering tubulin subunits into the growing MT end and 
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antagonising the depolymerising activity of the kinesin-13 protein 
MCAK (Cassimeris and Morabito, 2004). 
 
2. Aneuploidy and cancer 
Millions of cells divide every minute in humans and the fidelity of 
chromosome segregation is critical for maintaining the diploid 
status along cell generations. The mitotic checkpoint, also known 
as the spindle assembly checkpoint (SAC), has evolved as a 
surveillance mechanism. It is a complex signalling network that 
consists of several proteins, including MAD1 (mitotic arrest 
deficient 1), MAD2 (mitotic arrest deficient 2), BUB1 (budding 
uninhibited by benzimidazoles 1), BUBR1 (budding uninhibited by 
benzimidazoles 1) homolog beta, BUB3 (budding uninhibited by 
benzimidazoles 3) and CENP-E. The SAC delays the irreversible 
transition from metaphase to anaphase until the KTs of each 
replicated sister chromatid have correctly attached to spindle MTs. 
Impairment of checkpoint signalling determines premature mitotic 
exit before complete KT attachment and thus significantly 
increases the probability of chromosome mis-segregation (Figure 
5A).  
Mitotic errors can generate aneuploidy also with an intact mitotic 
checkpoint signalling (Figure 5B and C; Weaver and Cleveland, 
2006; Holland and Cleveland, 2012):  
-mis-segregation events occur when the KT of a single replicated 
chromosome becomes attached to MTs from both spindle poles, a 
situation known as merothelic attachment. Since the chromosome 
is attached and under tension, no mitotic checkpoint signal is 
generated. This attachment can produce a lagging chromosome that 
remains in the spindle midzone, becoming excluded from both 
daughter cells during cytokinesis, or segregating into one daughter 
cell, where it may form a micronucleus;  
- segregation errors resulting from multipolar spindles also cannot 
be prevented by the mitotic checkpoint, because the chromosomes 
make productive attachments;  
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- when three or more daughter cells are created by multiple 
cytokinetic furrows, aneuploid progeny is produced.  
 
 
 
    
 
 
Figure 5. Different pathways inducing aneuploidy. A) When the 
mitotic checkpoint is defective cells enter anaphase in the presence of 
unattached chromosomes, yielding unbalanced chromosome segregation. 
B) One KT may attach to MTs from both poles (merotelic): resulting 
lagging chromatids may mis-segregate or remain excluded from both 
daughter cells.  C) Multipolar spindles can give rise to highly aneuploid 
and often unviable daughter cells. Centrosome clustering yields a bipolar 
division even in the presence of multiple centrosomes, but produces 
merotelic attachments, as in B. 
 
Over a century ago the german zoologist Boveri described the 
effect of aneuploidy on organism development, proposing that 
aneuploidy has a detrimental effect on cell and organism 
physiology (Boveri 1902 and 1914). Today we know that 
aneuploidy is a common feature of human cancer, present in ~90% 
of solid human tumors and >50% of haematopoietic cancers 
(Mitelman et al., 2012). In addition to simple aneuploidy caused by 
rare mis-segregation of one or a few chromosomes, many tumor 
cells acquire chromosomal instability (CIN), a condition 
characterised by a high percentage of chromosome gain and loss 
during divisions (Holland and Cleveland, 2012). However, whether 
modified from Holland and Cleveland, 2009 
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aneuploidy is a cause or a consequence of malignant 
transformation remains hotly debated. The involvement of 
aneuploidy in driving or inhibiting tumorigenesis is related to its 
extent: moderate aneuploidy may be compatible with cell survival, 
with loss or gain of one or a few chromosomes promoting cell 
growth and tumorigenesis; on the contrary, high levels of 
aneuploidy determine cell death and tumor suppression (Figure 6; 
discussed in Weaver and Cleveland, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      
 
Figure 6. Aneuploidy can drive or inhibit tumorigenesis. A) Normal 
cells maintain a diploid genome with intact growth regulatory pathways, 
consistent with continued cell survival. B) Moderate aneuploidy can 
promote cell growth and tumorigenesis. C) High levels of genetic 
instability, or massive mis-segregation (10-15 chromosomes per 
division), result in cell death and tumor suppression. 
 
 
 
 
 
A. No genetic 
instability  cell survival 
 B. Moderate genetic 
instability  
tumorigenesis 
 C.  Massive genetic 
instability  
tumor suppression 
 (modified from Weaver and Cleaveland, 2007) 
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3. The Aurora kinase family of mitotic regulators 
Phosphorylation-based signalling networks play a key role in 
orchestrating spindle assembly and ensuring the correct sequence 
of mitotic events. Among mitotic kinases, Aurora-A plays a 
prominent role.  
Aurora-A belongs to the family of Aurora kinases: these 
serine/threonine kinases are key regulators of cell division, 
involved in many aspects of mitosis, including centrosome 
maturation, mitotic spindle formation, chromosome alignment, 
mitotic checkpoint activation: overall the are very important 
factors for accurate and equal segregation of chromosomes in the 
two daughter cells (Carvajal et al., 2006). 
The founding member of the family was identified in a screen for 
mitotic mutants that failed chromosome segregation in 
Saccharomyces cerevisiae (Chan et al., 1993), and independently 
in Xenopus laevis (Paris and Philippe, 1990) and Drosophila 
melanogaster (Glover et al., 1995): Xenopus Eg2 gene encodes for 
a kinase that was defined as a regulator of the G2/meiosisI 
transition in Xenopus oocytes and of mitotic spindle function in 
Xenopus eggs extracts (Andresson and Ruderman, 1998; Roghi et 
al., 1998). Severe mutations at the Aurora locus in Drosophila 
determined pupal lethality and a mitotic arrest characterised by the 
presence of monopolar spindles (Glover et al., 1995). Together, 
these early studies indicated a requirement for the kinase in mitotic 
progression.  
In mammalian cells three Aurora kinases have been described: 
Aurora-A, Aurora-B and Aurora-C (Figure 7). The genes have 
been mapped on chromosomes 20q13.2, 17p13.1 and 10q13 
respectively; proteins have an aminoacid sequence length ranging 
from 309 to 403. The catalytic domain is in the C-terminal region; 
Aurora-A and B have more than 70% of identity in their C-
terminal catalytic domain (Kollareddy et al., 2008; Nikonova et al., 
2012).  
Human Aurora-A and Aurora-B were first isolated in PCR screens 
to identify protein kinases that are overexpressed in breast and 
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colon carcinoma, respectively (Sen et al., 1997; Bischoff et al., 
1998; Bischoff and Plowman, 1999). It was evident that transcripts 
of both kinases were abundant (i) in tissues with a high mitotic 
index such as thymus primary epithelial cells and fetal liver, and 
(ii) in human tumor cell lines compared with matched normal 
controls. These profiles suggested that both kinases play a role in 
cell proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Aurora kinases. Human Aurora-A, -B and -C kinases are 
schematically represented. The A-box/D-box-activating domain (DAD) 
at the N-terminus, the D-box at the C-terminus and the position of the 
activation loop (green) within the catalytic domain (light brown) are 
shown.  
 
Although the three members of the Aurora family have a high level 
of similarity, they display distinct localization patterns and 
functions. 
- Aurora-C: Aurora-C was isolated in 1999 (Kimura et al., 1999) 
but it has been less characterised compared to the other family 
members, mainly due to its specificity of expression and function: 
Aurora-C expression is specifically limited to testis although 
overexpression in cancer cell lines is observed (Kimura et al., 
1999). Indeed a role of the kinase during spermatogenesis has been 
shown (Dieterich et al., 2007; Kimmins et al., 2007). Studies in 
HeLa cells showed that Aurora-C protein levels are up-regulated in 
modified from Carmena and Earnshaw, 2003 
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mitosis and that the kinase localises at centrosomes from anaphase 
to cytokinesis suggesting roles in centrosome function at late 
mitotic stages (Kimura et al., 1999).  
-Aurora-B is the “equatorial Aurora”. It localises at chromosomes 
during prophase and, in a dynamic manner, at the inner centromere 
region between sister chromatids during PM and metaphase; the 
kinase localises at central spindle MTs during anaphase, when its 
mobility is drastically reduced (Terada et al., 1998). This dynamic 
localisation gained to Aurora-B, with its regulatory and targeting 
components INCENP (inner centromere protein), survivin and 
borealin, the name of “Chromosomal passenger complex” (CPC). 
The CPC has pleiotropic mitotic roles (for a recent and extensive 
review see Carmena et al., 2012), briefly summarised below. It is 
essential for accurate chromosome segregation during cell division: 
via Aurora-B activity it has a key role in regulating KT/MT 
attachments, and in particular in the “correction” function, by 
destabilising unproperly connected KT/MT. Major Aurora-B 
targets relevant to this function are KT components responsible for 
MT binding and regulators of MT dynamics, such as the kinesin 13 
family member MCAK. Aurora-B is also involved in control of the 
SAC, by recruiting the SAC components and thus contributing to 
delay cell cycle progression until all KTs attain bipolar MT 
attachments. Finally, the CPC is involved in cytokinesis, by 
regulating central spindle formation, furrow ingression and 
abscission.  
In the next paragraph I will describe in more detail the regulation 
and roles of the Aurora-A member, which has been the object of 
this thesis. 
 
3.1. The Aurora-A kinase. 
Among the three mammalian Aurora kinases, Aurora-A has 
attracted significant attention, based on the evidence that it is 
overexpressed in many tumor types (Nikonova et al., 2012). 
Aurora-A associates with duplicated centrosomes during late S and 
G2 phases:  immunofluorescence (IF) staining is detected at the 
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PCM of centrosomes and increases as the cell cycle progresses. As 
the nuclear envelope breaks down and the bipolar spindle starts to 
form, the Aurora-A signal increases at  centrosomes and it remains 
associated with the mitotic poles, but also to the regions of MTs 
that are proximal to the centrosomes, until telophase. Then, low 
levels of the kinase can be detected at MTs of the central spindle 
(Figure 8) (Kimura et al., 1997). The bulk of the kinase is instead 
degraded at ana-telophase through an Anaphase Promoting 
Complex/Cyclosome (APC/C) and Cdh1 ubiquitin-dependent 
mechanism (Crane et al., 2004; Floyd et al., 2008).  
 
 
                 
 
 
Figure 8. Aurora-A in the cell cycle. Aurora-A (in red) strongly 
accumulates at centrosomes and is activated between the G2 and M 
phases. Aurora-A localises at the poles and at the spindle polar MTs. In 
late mitosis a fraction of Aurora-A is at the spindle midzone, while most 
of the protein is degraded before cytokinesis with only low levels 
detectable in G1 cells. DNA is in blue. 
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Aurora-A is a key regulator of mitosis and plays roles in different 
steps of mitotic progression. 
- Centrosome maturation and separation: the high frequency of 
monopolar spindles initially observed in Drosophila Aurora-A 
mutants indicated a role of Aurora-A in centrosome separation, 
that was later on confirmed in C. elegance and mammalian cells 
(Hannak et al., 2001; Giet et al., 2002; Marumoto et al., 2005). 
After they duplicate and separate, centrosomes recruit a number of 
proteins in a process known as maturation, which renders them 
capable of driving the abundant nucleation of MTs typical of 
mitosis. In late G2, Aurora-A contributes to centrosome 
maturation, by recruiting the PCM components γ-tubulin, 
centrosomine, LATS2 (Large Tumor Suppressor 2), TACC3 
(transforming acidic coiled-coil containing protein 3), NDEL1 
(nuclear distribution protein nude-like 1). Aurora-A 
phosphorylation of the LATS2 kinase promotes its recruitment to 
centrosomes, which is in turn required for the recruitment of γ-
tubulin (Toji et al., 2004). NDEL1, an evolutionarily conserved 
coiled-coil-containing protein, and TACC3, member of the 
transforming acidic coiled-coil family, form a complex with 
Aurora-A at centrosomes, that has a role in mitotic spindle 
formation, interacting with the ch-TOG/XMAP215 family (see 
paragraph 1.3) to stabilise MTs at centrosomes (Mori et al., 2007). 
- Mitotic entry: mitotic entry is promoted by the activation of 
CDK1 (Cyclin Dependent Kinase 1)/cyclin B1, which occurs 
initially at centrosomes. Aurora-A contributes to CDK1 activation 
by (i) phosphorylating the CDK1-activating phosphatases CDC25 
(Cell Division Cycle 25) B and C; (ii) activating PLK1 (polo like 
kinase 1), that induces the degradation of the CDK1-inhibitory 
kinase WEE1 (van Vugt et al., 2004). Aurora-A also controls the 
G2/M transition via interaction with BRCA1 (breast cancer 
associated gene1) mediating its localisation to the centrosome. The 
BRCA1 ubiquitin ligase interacts during mitosis with γ-tubulin and 
other centrosomal components to regulate G2/M progression and 
spindle assembly (Ouchi et al., 2004).  
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- Construction and control of a bipolar spindle: mutation or 
depletion of Aurora-A in different model systems causes formation 
of spindles with abnormally organised poles, including multipolar 
spindles, and mitoses with weak, sparse or short astral MTs 
(Hannak et al., 2001; Marumoto et al., 2003; De Luca et al., 2006). 
Aurora-A role in spindle pole formation may depend in part on its 
action in complex with the TACC proteins, as described above, in 
MT stabilisation at centrosomes, thus opposing the activity of the 
MT-destabilising kinesin MCAK; Aurora-A can also directly 
phosphorylate and regulate MCAK (De Luca et al., 2008; Zhang et 
al., 2008). Still, much has yet to be learned on how Aurora-A 
controls spindle pole organisation. 
 
3.2. TPX2: the major Aurora-A regulator 
Several factors modulate the activity, localisation and stability of 
Aurora-A in human cells (rev. in Carmena et al., 2009). The 
centrosomal pool of Aurora-A is activated by specific factors, i.e. 
Ajuba, HEF1 (Human Enhancer of Filamentation 1), PAK1 [p21 
Protein (Cdc42/Rac)-Activated Kinase 1] and Arpc1b (actin related 
protein 2/3 complex, subunit 1B); phosphatase PP2A (protein 
phosphatase 2A) shows mutual interdependence with Aurora-A for 
their co-localisation at the centrosome (which is also regulated by 
Plk1) and modulates Aurora-A stability through control of 
phosphorylation of the key residue Ser51. Other interactors 
regulate the stability [Cdh1, Chfr (checkpoint with forkhead and 
ring finger domains, E3 ubiquitin protein ligase), AURKAIP1] or 
activity [PP1 (protein phosphatase 1), PP1 Inhibitor-2, Gadd45a 
(growth arrest and DNA-damage-inducible, alpha)] of Aurora-A, 
but it is not clear whether they regulate specifically localised 
fractions or not. The spindle-associated fraction of Aurora-A is 
largely regulated by the MT-binding protein TPX2. 
TPX2 was originally identified in Xenopus as a spindle pole 
organizer involved in the recruitment of the kinesin Xklp2 
(Xenopus kinesin-like protein2) to MTs (Wittman et al., 1998) and 
subsequently in mammalian cells (Gruss et al., 2001); C. Elegans 
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and Drosophila TPX2-like proteins have been also described (Ozlu 
et al, 2005; Goshima, 2011). TPX2 is a100 kDa protein: the Xklp2 
MT-targeting domain, as well as an Eg5 binding region, are in the 
C-terminus (Brunet et al., 2004; Ma et al., 2010); MT binding 
domains are distributed along the protein sequence (Brunet et al., 
2004); the central region contains a NLS (nuclear localisation 
signal; Schatz et al., 2003); a KEN Box, important for TPX2 
degradation (Stewart and Fang, 2005), and the region required for 
Aurora-A binding, are located in the N-terminus (Figure 9A).  
TPX2 levels are cell cycle-regulated, with a peak in mitosis when 
it associates with spindle MTs, whereas during S and G2, it is 
diffusely distributed in the nucleus (Figure 9B; Gruss et al., 2002).  
TPX2 is required for stability of the spindle poles (Wittman et al., 
2000; Gruss et al., 2002; see paragraph 1.3), but also for activation, 
localisation and stability of Aurora-A (Figure 9C). In interphase, 
TPX2 is inhibited by the interaction with importin-alpha and -beta 
(cargo receptors for nuclear transport). After nuclear envelope 
breakdown, importins are displaced by the small GTPase Ran (a 
regulator of nuclear transport) and TPX2 is free to bind Aurora-A, 
which gets activated (Gruss and Vernos, 2004). The mechanism 
through which TPX2 activates Aurora-A has been characterised: 
TPX2 binding induces a conformational change in the kinase, 
modifying the position of a key residue (Thr288) in the Aurora-A 
three-dimensional structure and interfering with the inhibitory 
activity of PP1 (Protein phosphatase 1) upon Aurora-A (Figure 
9C). Thus, TPX2 binding stabilises Thr288-phosphorylated 
Aurora-A, which represents the active form of the kinase (Bayliss 
et al., 2003; Eyers et al., 2003; Tsai et al., 2003). TPX2 is also 
required to target Aurora-A to the spindle (Kufer et al., 2002; De 
Luca et al., 2006). We recently reported that TPX2 controls 
Aurora-A stability in human cells: Aurora-A protein levels 
decrease in PMs lacking TPX2, in a proteasome- and Cdh1- 
dependent manner, and the interaction between Aurora-A and 
TPX2 is required for protecting Aurora-A from degradation  
(Giubettini et al., 2011).  
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Figure 9. The Aurora-A activator TPX2. A) Representation of TPX2 
functional domains. B) TPX2 (green) in interphase and mitotic cells. IF 
images show merge with DNA (in blue). Bar: 10 µm. C) Schematisation 
of TPX2 regulation on Aurora-A. High: TPX2-mediated Aurora-A 
localisation to spindle MTs. Low: TPX2 interferes with the inhibitory 
activity of protein phosphatase PP1 upon Aurora-A. 
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3.3. Aurora-A and cancer 
The Aurora-A gene locus is on chromosome 20q13.2, within a 
region that is frequently amplified in many tumor types. 
Indeed, the Aurora-A gene was first named as BTAK (Breast 
Tumor Activated Kinase), because its mRNA was found to be 
overexpressed in breast tumors (Sen et al., 1997); next, other 
independent studies identified the up-regulation of Aurora-A as a 
common feature of multiple solid cancers, including colorectal, 
breast, ovarian, gastric, prostate, neuroblastoma and cervical, in 
both primary tumor tissues and cell lines (Bischoff et al., 1998; 
Zhou et al., 1998; Tanaka et al., 1999; Pihan et al., 2001; Sakakura 
et al., 2001; Gritsko et al., 2003; rev. in Vader and Lens, 2008). 
Aurora-A protein levels can be altered as a consequence of gene 
amplification, changes of gene expression or protein stabilisation. 
Aurora-A transcription is regulated by different pathways (STA5a, 
estrogen/GATA3, HIF1) (Lee et al., 2008; Jiang et al., 2010; Xu et 
al., 2010) that are frequently elevated in cancer. In addition many 
Aurora-A interactors, that normally protect Aurora-A from protein 
degradation (IQ-GAP1, NEDD9/HEF1) are up-regulated in cancer 
(Pugacheva et al., 2005; Tikhmyanova et al., 2010). On the 
contrary, many factors involved in the physiological Aurora-A 
degradation during the cell cycle, such as Chfr, are downregulated 
in many cancers (Sanbhnani et al., 2012).  
Aurora-A overexpression may contribute to cell transformation 
through different routes. For instance, unlike in normal cells, in 
some tumor cells Aurora-A is detected diffusely in the cytoplasm 
(Gritsko et al., 2003), giving rise to aberrant phosphorylation of 
cytoplasmic proteins. In addition, Aurora-A phosphorylates the 
p53 tumor suppressor protein, thus inactivating it (Liu et al., 2004); 
a large number of studies have reported complex direct and 
indirect relationships between Aurora-A, p53 and carcinogenesis 
(Chiang, 2012). Aurora-A also regulates factors involved in 
cancer-related pathways, e.g. BRCA1 (Ouchi et al., 2004; 
Sankaran et al., 2007), N-Myc (Otto et al., 2009), NF-kB and IkBα 
(Briassouli et al., 2007).  
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Given that Aurora-A is a key regulator of mitosis, cell division 
defects may also account for the tumorigenic potential of its 
overexpression. Following elevated Aurora-A expression in cell 
cultures, mitosis is characterised by the presence of multiple 
centrosomes, overriding of the spindle checkpoint and failure of 
cytokinesis, developing polyploidy and progressive chromosomal 
instability (Zhou et al., 1998; Meraldi et al., 2002; Anand et al., 
2003).  
Despite these evidences, a direct correlation between a sufficient 
and direct role of Aurora-A overexpression and cell transformation 
remains controversial. Transformation assays with Aurora-A in 
different cell lines as well as mouse models designed to assess the 
direct contribution of Aurora-A to tumorigenesis yielded 
controversial results and only one set of in vivo models to date 
clearly supports the notion that Aurora-A overexpression can drive 
tumor formation in mice (Bischoff et al., 1998; Zhou et al., 1998; 
Anand et al., 2003; Zhang et al., 2004; Fukuda et al., 2005; Wang 
et al., 2006; Warner et al., 2008; Li et al., 2009) Thus, evidences 
supporting the definition of Aurora-A as an oncogene are 
contradictory; the specific molecular background and/or gene 
profile of the experimental system under examination could 
modulate the ultimate effect of Aurora-A overexpression.  
Studies of the best characterised allelic variants of Aurora-A 
(Phe31Ile and Val57Ile) have confirmed the idea that concomitant 
alterations in other factors modulate the oncogenic capacity of 
Aurora-A: although there is an overall consensus that these alleles 
confer increased risk of breast and colon cancer (Gautschi et al., 
2008) and promote genetic instability and malignant 
transformation (Hienonen et al., 2006; Torchia et al., 2009), their 
effects are influenced by the tissue type, patient age and tumor 
stage (Ju et al., 2006; Chen et al., 2007; Gu et al., 2007). 
Interestingly, neither of these mutations affects the Aurora-A 
catalytic domain directly, but both can potentially affect the 
interaction of Aurora-A with its regulators, partners or substrates. 
Thus, studies on Aurora-A overexpression alone indicate a clear 
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potential, and yet a broad variability, as an oncogenic agent, 
leaving much room for partners to modulate the full oncogenic 
potential of Aurora-A. 
 
4. Aurora-A as a novel target in anti-cancer terapy 
4.1. Traditional anti-mitotic agents in anti-cancer therapy 
Many drugs that are used in anti-cancer therapy are “anti-
proliferative” drugs. They act by perturbing the proliferative cycle 
of tumor cells: tipically, DNA-damaging agents and inhibitors of 
cyclin-dependent kinases arrest cell cycle progression at different 
stages. Anti-mitotic drugs selectively perturb progression through 
mitosis (Janssen and Medema, 2011). Currently, the anti-mitotic 
drugs that have been approved for clinical use target MTs. The two 
conventional MT-targeting drugs are taxanes and Vinca alkaloids, 
both of which have proven effective in the treatment of different 
types of cancer: Taxol is frequently used in the treatment of breast 
and ovarian cancers, while Vinca alkaloids are used in combination 
with other drugs for the treatment of hematological cancers. The 
Vinca alkaloids at low concentrations inhibit MT dynamics, and at 
high concentrations induce MT depolymerisation. Taxol stabilises 
MTs, by altering depolymerisation dynamics and thus preventing 
normal spindle assembly (Gascoigne and Taylor, 2009; Janssen 
and Medema, 2011). As a consequence of the absence of MT 
dynamics, tension is not produced across sister chromatids (Kelling 
et al., 2003) and correct chromosome bi-orientation is not 
achieved. This situation determines the chronic activation of the 
spindle assembly checkpoint that leads to mitotic arrest 
(Musacchio and Salmon, 2007). 
Although these anti-mitotic drugs have been used with clinical 
success, they also display negative effects: i) some patients 
respond well to the treatment, but others rapidly acquire resistance 
to the treatment; ii) toxicity is a major limitation: anti-MT drugs 
affect the division of normal cells too, as well as MT-related 
functions in non-dividing cells, like peripheral neurons, with 
consequent neurotoxicity and permanent damage (Rowinsky et al., 
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1993; Gascoigne and Taylor, 2009). To minimise neurological 
effects, new agents are being developed that interfere with mitotic 
progression without altering MT dynamics in non-dividing cells. 
This new class of potential therapeutic agents include compounds 
that inhibit the activity of mitotic kinases. 
 
4.2. Aurora-A inhibitors and novel strategies in tumor 
treatments. 
Many mitotic inhibitors that are under clinical evaluation for anti-
cancer therapy are directed against the three members of the 
Aurora family. These kinases are proposed as potential targets 
given their clear association with tumorigenesis (Lapenna et al., 
2009). The proof of concept study to address the possibility to use 
Aurora-A as a therapeutic target was performed by Hata and 
collaborators in 2005 (Hata et al., 2005). Using RNAi to 
knockdown Aurora-A expression in cultured pancreatic cancer 
cells, in which the kinase is overexpressed, they observed that in 
vitro cell growth as well as tumorigenicity in mice were strongly 
suppressed. This pioneering study was the starting point for a large 
number of studies characterising Aurora-A as a target in cancer 
therapy. Supporting this idea, early in vitro experiments with the 
first Aurora kinase chemical inhibitors demonstrated that they 
affect viability only on the dividing cells while the non dividing 
cells remained viable (Ditchfield et al., 2003). The anti-tumor 
activities of these inhibitors have also been evaluated in xenografts 
and a few preclinical studies have progressed to the early stages of 
clinical trials (Katayama and Sen, 2010). All the Aurora kinase 
inhibitors currently in development for clinical use are small 
molecules designed to bind to the ATP-binding pocket that is 
highly conserved among kinases, and for this reason many of these 
compounds are active, to some extent, against multiple structurally 
related kinases (ABL, SRC, JAK2, VEGFR2, FLT3 and FGFR1); 
this observation influenced their clinical development towards 
certain tumor types with relevance to their off-target activity 
(Nikonova et al., 2012). Even more, it has been very difficult to 
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find compounds which are able to discern between Aurora-A and 
Aurora-B. Given the different roles of these kinases in cell 
division, discussion is ongoing on the therapeutic value of 
targeting either of them specifically, or both. Initially, Aurora-A 
was considered as a therapeutically more valuable target, given its 
clear involvement in tumorigenesis and the protective role of 
Aurora-B against aneuploidy generation; still, no clinical data have 
shown specific inhibitors to be more or less therapeutically 
valuable than multi- or pan-Aurora inhibitors so far (rev. in Green 
et al., 2011).   
Aurora-A kinase inhibitors activity has been studied in a broad 
range of hematological and solid tumors with good results in 
disease stabilisation in a minority of patients (Table 1). 
 
         
 
Table 1. Aurora-A inhibitors. The most specific Aurora-A inhibitors 
under evaluation in cinical trials are listed. The central column shows the 
tumor types in which the effects of the inhibitor are being evaluated. In 
the right column the current clinical evaluation status is represented.  
 
MLN8054 was the first specific Aurora-A inhibitor studied, which 
is approximately 40 fold more active towards Aurora-A compared 
to Aurora-B. It has completed three phase I studies with promising 
Inhibitor! Tumor types! Current status!
ENMD-2076!
myeloma, breast  cancer, 
leukemia, colorectal cancer, 
ovarian  cancer!
phase I/II!
MLN-8237!
lymphoma, leukemias, 
myeloma, breast cancer, 
prostate cancer!
phase I/II!
MK-5108!
breast cancer, cervix cancer, 
colorectal cancer, ovarian 
cancer, pancreas neoplas !
phase I!
XL-228! lung, leukemia! phase I!
KW-2449! leukemia! phase I!
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early indication of anti-tumor activity. However somnolence was 
observed associated with the treatment, that was unexpected and 
remains poorly understood. This Aurora-A inhibitor, that is 
structurally similar to benzodiazepines, may act on GABA alpha1 
receptor and consequent benzodiazepine-like central nervous 
system effects may be involved (Macarulla et al., 2010; 
Chakravarty et al., 2011; Dees et al., 2011). At present, trials 
involving MLN8054 have been arrested. 
Numerous clinical trials are ongoing using a second generation 
compound, MLN8237, the most specific inhibitor of Aurora-A to 
have arrived to phase II. It shares structural homology with 
MLN8054, but has 4-fold greater inhibitory potency for Aurora-A 
kinase and a decreased tendency to cause somnolence. MLN8237 
is being tested both as a single agent and in combination with other 
anti-cancer compounds (reviewed in Green et al., 2011). Abundant 
preclinical data had provided support for combining Aurora-A 
inhibitors with a wide variety of existing agents targeting the 
Aurora-A partners and effectors; indeed, phase I trials with 
MLN8237 have shown that its combination with Taxol is well 
tolerated and that anti-tumor activity is observed in ovarian and 
breast cancer (Kelly et al., 2012). Modest clinical effects have been 
observed in the solid tumors studies with MLN8237 alone; the 
reasons are unclear, particularly with respect to results obtained in 
cell lines and xenografts. One possibility for this discrepancy 
might be the existence of redundant signalling pathways in tumor 
cells allowing for bypass signalling (i.e., drug-selected activation 
of Aurora-A partners or effectors) to drive cellular proliferation 
despite the blockade of Aurora-A. Active research is ongoing to 
understand the cellular basis of Aurora-A inhibitors mode of action 
and thus improve on their use in the clinics. 
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AIM 
 
The aim of my PhD project was to investigate the mitotic roles of 
the Aurora-A kinase in human cells and the effects of its 
deregulation on cell division. 
In previous works (De Luca et al., 2006 and 2008) we had 
observed that depletion of Aurora-A by RNAi in human U2OS 
osteosarcoma cells determines the formation of spindles with 
multiple poles. We had also observed that under these conditions 
regulators of MT dynamics are mis-localised: ch-TOG, a MT-
stabilising factor, increases at spindle poles; its major antagonist, 
MCAK, a kinesin with MT-destabilising activity, decreases at 
poles. Spindle pole fragmentation is abolished when ch-TOG and 
Aurora-A are co-inactivated, indicating a correlation between the 
increase of ch-TOG at spindle poles and the formation of 
extrapoles. Building on these observations, in the first part of my 
PhD project, I investigated the molecular mechanisms through 
which Aurora-A exerts this newly identified function in control of 
spindle pole integrity.  
The observation that Aurora-A inhibition induces supernumerary 
spindle poles also raises concern about Aurora-A inhibition-based 
therapeutic protocols that are under evaluation in anti-cancer 
therapy: indeed, unforeseen dangerous effects may occur, due to 
aneuploidy induction. An in-depth understanding of the effects of 
Aurora-A inhibition may help to interpret the results from ongoing 
clinical trials and to improve on the use of Aurora-A inhibition as 
an anti-cancer strategy.  During my PhD I therefore evaluated the 
cellular effects of the Aurora-A inhibitor MLN8237, which is 
being tested in clinical trials and has been mainly characterised 
using whole cell population approaches. Cellular responses to anti-
mitotic drugs are heterogeneous, and single cell analysis can reveal 
stochastic events and cell-to-cell variability that cannot be 
appreciated otherwise, providing a better understanding that can 
importantly contribute to predict whether these compounds will 
have clinical efficacy. I therefore focused on single-cell 
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microscopy-based approaches, with the final aim of identifying 
relevant parameters determining either effective cell death, or, on 
the contrary, the generation of aneuploid cells, and rationalise the 
therapeutic use of Aurora-A inhibitors. 
Data from the literature suggest that the specific molecular 
background modulates the ultimate effect of Aurora-A 
overexpression in tumor formation: expression levels of activators 
or substrates may therefore be relevant. Stemming from the 
observation that the MT-associated protein TPX2, besides its 
known roles in regulating the activity and the localisation of 
Aurora-A, also modulates its protein stability (Giubettini et al., 
2011), I hypothesised that its deregulation may contribute to elicit 
the full oncogenic potential of Aurora-A in transformed cells. In a 
data mining effort, I searched for evidence of TPX2 
overexpression, and Aurora-A/TPX2 co-overexpression, and 
suggest that the complex, as a unit, may contribute to tumor 
formation. 
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RESULTS 
 
1. Aurora-A controls spindle pole integrity by regulating 
microtubule-associated forces  
As recalled in the Aim, spindle poles are fragmented in mitotic 
cells where Aurora-A is inactivated by RNAi; concomitant 
accumulation of the MT-stabilising factor ch-TOG is observed (De 
Luca et al., 2008). The first aim of my PhD project was to 
elucidate the mechanisms by which Aurora-A regulates the 
organisation of spindle poles.  
 
1.1. Aurora-A inactivation yields hyperstabilisation of mitotic 
spindle microtubules. 
I first asked whether the altered levels of ch-TOG at spindle poles 
in Aurora-A-interfered (Aurora-Ai) mitoses modify the dynamic 
properties of spindle MTs. MTs are quickly depolymerised when 
incubated on ice. Assaying the sensitivity of MTs to 
depolymerisation at low temperatures, in the presence or absence 
of a specific protein, can be used to assess the “protective” effect 
conferred by the factor, or absence thereof. Thus, I used this assay 
to observe the effect of Aurora-A inactivation on MT dynamic 
properties. I performed a time-course analysis, incubating the 
cultures for 10, 15 and 20 minutes on ice, and observed the status 
of polymerisation of MTs in prometa- and metaphase (PM/M) cells 
(Figure 10). I classified the cells as: a) with a normal spindle 
(“polymerised”), b) with partially depolymerised MTs and c) with 
fully depolymerised MTs. In GL2-interfered (GL2i) cultures, 
interfered for 48 hours with neutral small interfering RNA 
(siRNA), cells with polymerised MTs quickly disappeared (less 
than 1% after 15 minutes of ice incubation). Cells with partially 
depolymerised spindles, displaying disorganised MTs with clear 
centrosomal origin, are present at 10 to 15 minutes of ice 
incubation; after 20 minutes on ice there is a decrease of this class 
of cells and the predominant status (over 80% of all PM/M) is 
represented by cells with fully depolymerised MTs in which 
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centrosomes are totally devoid of MTs and only the more stably 
KT- attached MTs (K-fibers) are evident (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Aurora-A inactivation induces hyperstabilisation of 
spindle MTs. A schematisation of the protocol is shown. PM and M 
cells from control (GL2) and Aurora-Ai cultures incubated on ice for the 
indicated times were classified according to the status of MTs, 
exemplified in the IF panels. The rightmost column indicates the number 
(n) of scored PM/M cells in 2 independent experiments; mean values (%) 
and s.d. (italics) are indicated. 
 
In Aurora-Ai PM/M the kinetics of depolymerisation is 
significantly slower compared to control cells. After 20 minutes of 
ice incubation the percentage of cells with fully depolymerised 
MTs is only about 50%, while the remaining 50% still display 
partially depolymerised MTs, a condition observed in <20% of 
mitoses in control cultures at this time point (Figure 10).  
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Thus, the ice-induced depolymerisation assay indicates a resistance 
of MTs to depolymerise, indicative of a MT hyperstabilisation, in 
cells depleted of Aurora-A. 
 
 
1.2. Microtubules hyperstabilisation in Aurora-Ai mitoses: the 
contribution of ch-TOG.  
In order to investigate whether ch-TOG, which accumulates at 
poles in Aurora-Ai mitoses (De Luca et al, 2008), is also involved 
in the observed hyperstabilisation of MTs, I performed a set of 
experiments in which I co-depleted ch-TOG and Aurora-A by 
RNAi. I then observed the status of polymerisation of MTs in the 
double-interfered cultures compared with control and with the 
single-interfered cultures (Aurora-Ai or ch-TOGi). I analysed 
PM/M cells after 15 minutes of ice incubation (Figure 11).  
             
 
Figure 11. Aurora-A and ch-TOG modulate the stability of spindle 
MTs in opposite manners. Cells interfered (i) with the indicated 
siRNAs were incubated on ice for 15 minutes. Histograms represent the 
distribution of PM/M in the three MT categories identified in Figure 10 
(at least 350 counted cells per condition, 2 experiments). Error bars 
denote s.d. 
Italia Anna Asteriti 
                                                                                                       Pag 42  
In ch-TOGi cultures, ice-induced MT-depolymerisation is faster 
than in control cultures; this is consistent with the loss of the MT-
stabilising activity of ch-TOG. In cell cultures in which both 
Aurora-A and ch-TOG are inactivated, the MT hyperstabilisation 
caused by Aurora-A inactivation alone (see Figure 10) is reduced 
and sensitivity to ice-induced depolymerisation is restored.  
This result suggests a role of ch-TOG in the altered stability of 
MTs in Aurora-A-depleted cells. We had previously shown that 
ch-TOG activity is required for spindle pole fragmentation in 
Aurora-Ai mitoses, and that ch-TOG co-depletion reduces the 
percentage of mitoses with spindle extrapoles in Aurora-Ai 
cultures (De Luca et al., 2008). 
To test whether there is a correlation between the altered stability 
of MTs and the formation of mitotic spindle extrapoles, I examined 
how Aurora-Ai PM/M cells with extrapoles are distributed in the 
three classes of MT polymerisation (polymerised, partially 
depolymerised, depolymerised) after 15 minutes of ice incubation 
(Figure 12). Pole fragmentation was particularly represented (16%) 
and statistically significant compared to GL2i, among Aurora-Ai 
PM/M with ice-resistant MTs. By contrast, mitoses with partially 
or fully depolymerised MTs in Aurora-Ai cultures do not display a 
statistically significant occurence of pole fragmentation compared 
with controls. Mitoses where ch-TOG and Aurora-A were co-
inactivated generally assemble a normal bipolar spindle; the rare 
cells that displayed spindles with extrapoles showed no specific 
association with the status of depolymerisation of MTs and were 
uniformly distributed among the different categories similarly to 
control cultures. 
This shows that the absence of Aurora-A yields mitotic spindle 
pole fragmentation in those mitoses in which MTs are 
hyperstabilised. 
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Figure 12. Correlation between PM/M cells with extrapoles and MT 
stability. Histograms represent the distribution of mitoses with 
fragmented spindle poles among the MT stability categories shown in 
Figure 10 (examples are shown in the IF panels). Around 700 PM/M 
were counted for each interference (2 experiments). Error bars represent 
s.d. **: p < 0.001, χ2 test. Scale bar: 10 μm. 
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1.3. Eg5 is required for spindle pole fragmentation induced by 
Aurora-A inactivation. 
In previous work we observed that spindle pole fragmentation in 
Aurora-A-depleted mitoses occurs in a MT-dependent manner (De 
Luca et al., 2008); results presented in the previous paragraph 
demonstrate that spindle extrapoles manifest preferentially in 
PM/M cells harbouring hyperstable MTs. This evidence suggests 
that when Aurora-A is inactivated, spindle poles may be subjected 
to an excessive MT-originated pressure (see Introduction for a 
discussion of MT-associated forces), due to the altered stability of 
MTs, which is responsible for fragmentation of centrosomes. If this 
hypothesis is correct, inactivation of centrosome-directed forces, 
that contribute to generate pressure on centrosomes, should inhibit 
spindle pole disruption in Aurora-A-depleted cells (Figure 13).  
 
 
 
Figure 13. Hypothesised mechanism for spindle pole fragmentation 
in Aurora-Ai mitoses. MT-associated forces are normally balanced with 
respect to each other and with the action of MT stabilysing factors. In 
Aurora-Ai cells an imbalance in the forces directed towards centrosomes 
may determine an excessive pressure on poles and their fragmentation. 
Factors and forces investigated in the experiments described in this thesis 
are schematised. 
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The Eg5 kinesin is a motor protein that moves along antiparallel 
MTs in the plus-end-direction, thus generating a force directed 
towards centrosomes (Sharp et al., 2000; see Introduction). Eg5 
activity is specifically inhibited by MON (Mayer et al., 1999; 
Kapoor et al., 2000); in order to asses whether Eg5-generated 
forces affect spindle pole fragmentation in a condition of Aurora-A 
depletion, I treated Aurora-Ai cultures with MON. Simultaneous 
staining of MTs (using an alpha-tubulin-directed antibody) and 
centrosomes (with a pericentrin-directed antibody) (Figure 14) 
showed that MON treatment of Aurora-Ai cells significantly 
reduces the fragmentation of centrosomes and the formation of 
spindle extrapoles compared with Aurora-Ai cells with active Eg5, 
with a parallel increase of mitoses with monopolar spindles, the 
typical phenotype observed following MON treatment (Kapoor et 
al., 2000).  
To further confirm the role of Eg5-mediated forces in the 
formation of fragmented poles in Aurora-Ai mitoses, I took 
advantage of the reversibility of MON to restore Eg5 activity. I 
washed-out MON with the addition of MON-free medium and Eg5 
activity was rapidly resumed, as monitored by the recovered ability 
of centrosomes to move apart; in parallel, spindle pole 
fragmentation rapidly returned to comparable levels to those seen 
in Aurora-Ai cultures (Figure 14). This result shows that, in 
Aurora-A-depleted cells, restoring Eg5 activity is sufficient to 
generate spindle pole fragmentation induced by inactivation of the 
kinase. This is consistent with the idea that MT-associated forces 
directed towards centrosomes are imbalanced in Aurora-Ai mitoses 
and underlights the key role of MT-associated forces in the spindle 
pole fragmentation event caused by Aurora-A inactivation. 
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Figure 14. Spindle pole fragmentation in Aurora-Ai mitoses depends 
on Eg5 activity. A schematisation of the protocol is shown (time 
intervals not represented to scale). IF panels show spindles displaying 
normal or fragmented poles in control and Aurora-Ai cells, respectively 
(first and second row); monopolar spindles in Aurora-Ai cells treated 
with MON (third row); spindles displaying pole fragmentation in Aurora-
Ai cells after MON release (MON-rel; lower row). Histograms represent 
the percentage of PM/M displaying fragmented poles, as assessed by 
alpha-tubulin (left) and pericentrin (right) staining (200 to 400 counted 
cells per condition in 2-4 experiments; s.d are shown). *: p < 0.01, **: p 
< 0.001, χ2 test. Scale bar: 10 μm. 
 
 
1.4. Interfering with kinetochore-microtubule attachments 
prevents spindle pole fragmentation induced by Aurora-A 
inactivation 
In the experiments in which I inhibited Eg5 it was still possible 
that spindle formation was blocked at a stage that preceded the 
fragmentation of poles induced by Aurora-A inactivation. To 
distinguish between a specific temporal implication of Eg5 and a 
global alteration of spindle forces orchestration in Aurora-A-
depleted cells, I used an independent approach to reduce MT-
associated forces directed towards poles. During normal spindle 
assembly, K-fibers-generated forces contribute to centrosome 
separation during PM and need counteracting by motor-associated 
MT-focusing activities at poles (see paragraph 1.3 in Introduction): 
thus, destabilisation of KT-MTs attachments would reduce KT-
generated forces directed towards centrosomes and hence the 
pressure applied on spindle poles. To test whether this condition 
restores spindle bipolarity in Aurora-Ai cells, I co-depleted by 
RNAi Aurora-A and the KT-protein Nuf2, a key factor involved in 
the formation of stable KT-MTs attachments (see paragraph 1.3 in 
Introduction; results are shown in Figure 15). The occurrence of 
PM/M with spindle extrapoles was significantly reduced in 
Nuf2i/Aurora-Ai cultures compared to those defective for Aurora-
A alone. This evidence confirms that KT-MT attachments are 
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involved in the generation of mitotic spindle pole fragmentation in 
a condition of Aurora-A depletion.  
 
 
 
 
Figure 15. Spindle pole fragmentation in Aurora-Ai mitoses depends 
on active Nuf2. A. The efficiency of Aurora-A and Nuf2 depletion after 
RNAi was assessed by WB (left panels) and IF (right panels) analyses. 
B. Histograms represent the percentage of PM/M displaying fragmented 
spindle poles (alpha-tubulin staining) after transfection with the indicated 
siRNAs (at least 200 cells per condition, 2 experiments). Error bars 
denote s.d. *: p < 0.01, **: p < 0.001, χ2 test. Scale bar: 10 µm 
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It is known that Nuf2 interference yields the appearance of 
elongated mitotic spindles (DeLuca et al., 2002; Manning and 
Compton, 2007). These elongated figures were unaffected by the 
simultaneous inactivation of Aurora-A (Figure 16). Thus, the co-
inactivation of Aurora-A and Nuf2 does not restore the overall 
spindle shape but specifically restores spindle bipolarity, by 
preventing spindle pole fragmentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Elongated spindles induced by Nuf2 RNAi are not rescued 
in Aur-A/Nuf2 co-inactivated cells. IF images show spindles (alpha-
tubulin) in control and Nuf2i mitoses. Spindle axes are schematised on 
the right: the pole-to-pole axis is longer in Nuf2i cells compared to 
controls. Histograms show the percentage of mitoses displaying such 
abnormal spindles under the distinct examined conditions.About 200 
counted PM/M per condition in 2 experiments. Error bars denote s.d. *: p 
< 0.01, **: p < 0.001, χ2 test. Scale bar: 10μm.  
 
In conclusion, results shown in this first part highlight a novel 
function of Aurora-A in orchestrating the balance between MT-
associated forces that ensure the proper organisation of mitotic 
spindle poles.  
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2. Effects of a small molecule inhibitor of Aurora-A activity at 
the single cell level in human cells  
 
Our RNAi data in human U2OS cells indicated that inhibition of 
Aurora-A induces the fragmentation of mitotic spindle poles as a 
consequence of the key role of the kinase in the control of the 
balance of MT-associated forces within the spindle. Mis-assembled 
spindles can determine mis-segregation of chromosomes in the two 
daughter cells and hence aneuploidy that, if moderate, can drive 
tumorigenesis (see Figure 6). This may be a critical issue in the 
proposed use of Aurora-A chemical inhibitors in cancer therapy 
(Green et al., 2011) and deserves better insight. Since the overall 
response of cultures to anti-mitotic compounds is in fact a “profile 
of cell fates”, single-cell analysis, e.g. live cell imaging, may add 
relevant information on cell-to-cell variability and stochastic 
events that would go unnoticed in whole cell population studies 
(Gascoigne and Taylor, 2009). I therefore decided to undertake 
single cell analyses in human cells using MLN8237, one of the 
most specific inhibitors of Aurora-A that are under evaluation in 
clinical trials. 
 
 
2.1. MLN8237 inhibition of Aurora kinases in pre-
synchronised cultures 
Unlike Aurora-A inhibition by RNAi, chemical inhibition of 
Aurora-A affects the activity of the kinase, while leaving the total 
levels of the protein unaltered (Figure 17). I set up a protocol in 
which U2OS cells pre-synchronised at the G1/S transition by 
thymidine treatment were treated with MLN8237 after 6 hours 
from thymidine release, when cells were in late S-phase or early 
G2. Cells were then harvested after 4 hours in order to analyse 
mitotic cells (Figure 17). 
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Figure 17. MLN8237 treatment drastically reduces Aurora-A 
activity. A. The experimental protocol is shown (time intervals not 
represented to scale). The efficiency of Aurora-A activity inhibition after 
MLN8237 treatment was assessed by WB analysis using phospho-
Thr288-Aurora-A (p-Aurora-A); Aurora-A total levels were checked for 
control; actine was the loading control; extracts are obtained from mitotic 
cells harvested by shake off. One series of extracts was treated with 
nocodazole (NOC) for 4 hours before harvesting in order to enrich in PM 
figures.  
 
 
To test the effectiveness of MLN8237 treatment, I first performed 
a Western immunoblotting (WB) analysis using two different 
concentrations (20 and 50 nM) of MLN8237, which had proven 
effective in previous publications (Zeng et al., 2010; Manfredi et 
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al., 2011). 4 hours after treatment with both doses of MLN8237 no 
phospho-Thr288 (active)-Aurora-A was detectable in mitotic cell 
extracts (Figure 17). Aurora-A protein levels were instead 
unchanged. 
To obtain more detailed information, I measured Aurora-A activity 
at the single cell level using the anti-Aur-A-phospho-Thr288 IF 
staining in dose-response assays (from 5 nM to 250 nM). 
Treatments with 5 nM and 10 nM MLN8237 yields a significant 
inhibition of Aurora-A auto-phosphorylation, compared to controls 
(DMSO alone), but a residual fraction (25-30%) of active Aurora-
A is still evident; at 20 nM there is a virtually complete Aurora-A 
inactivation (Aurora-A auto-phosphorylation is about 10% 
compared to controls) and with higher concentrations the average 
residual Aur-A-phospho-Thr288 signal at spindle poles was below 
5% compared to controls (Figure 18).  In order to confirm the 
specificity of action of the MLN8237 inhibitor in single cell 
analyses I measured Aurora-B activity by staining cultures with the 
anti-phospho-Thr232 (active)-Aur-B antibody (Figure 18). It is 
known that high concentrations, i.e. 250 nM, of MLN8237 inhibit 
Aurora-B activity too (Manfredi et al., 2011). Surprisingly, I 
noticed that partial but highly significant Aurora-B inhibition was 
already occurring when using 50 nM MLN8237 (residual phospho-
Thr232-Aur-B signal was below 45% compared to controls), 
indicating that in U2OS cells there is a narrow window (20 to 50 
nM) in which the inhibitor is really specific for Aurora-A. 
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Figure 18. Effects of MLN8237 treatment on Aurora-A and Aurora-
B activity. A schematisation of the experimental protocol is shown (time 
intervals not represented to scale). The efficiency of Aurora-A and 
Aurora-B activity inhibition after MLN8237 treatment was assessed by 
IF analysis. Selections (at poles and chromosome respectively) used for 
P-
Au
r-B
 Si
gn
al 
Int
en
sit
y !
(ar
bit
rar
y u
nit
s) 
!
4h# MLN8237#
5nM#
10nM#
20nM#
50nM#
250nM#
P-
Au
r-A
 Si
gn
al 
Int
en
sit
y!
 (a
rbi
tra
ry 
un
its
) !
**!
DMSO! 5! 10! 20! 50! 250!
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
MLN8237!
0
50000000
100000000
150000000
200000000
250000000
DMSO! 5! 10! 20! 50! 250!
**!
MLN8237!
nM!
nM!
γ-tub /p-Aurora-A!
DAPI/ p-Aurora-B!
Partial Aur-A! Complete Aur-A/partial Aur-B!
Complete Aur-A & B!Complete Aur-A!
Inactivation extent: 
Italia Anna Asteriti 
                                                                                                       Pag 54  
measuring signal intensity are shown in the IF panels (scale bar: 5 µm). 
Each diamond in the graphs represents the signal intensity of phospho-
Thr288-Aurora-A (p-Aurora-A) or phospho-Thr232-Aur-B (p-Aurora-B) 
in a single cell. Experiments were repeated 2/3 times and 20 cells per 
experiment were measured; one representative experiment is shown. 
**p<0.0001, Student’s t-test was applied. 
 
 
2.2. Delayed mitotic entry and prolonged mitosis in cells 
treated with MLN8237. 
To study the biological effects of MLN8237 at the single cell level, 
I started a collaboration with the Advanced Light Microscopy 
Facility (ALMF) of EMBL of Heidelberg, thanks to the selection 
within the Proof of concept studies of the Euro-BioImaging project 
(http://www.eurobioimaging.eu). I performed a short visit to the 
ALMF, during which I could use high-throughput microscopy 
instrumentations, to get a first “global view” of the effects of 
MLN8237 in pre-synchronised U2OS cultures in dose response 
experiments; sample numerosity associated with the possibility to 
observe the long term outcome of the cultures were important 
features of the high throughput microscopy experiments. Cultures 
treated as in Figure 18 were video-recorded from the moment of 
treatment until 48-60 hours later; concomitant recording of all 
analysed MLN8237 doses (about 20 fields per condition) was 
possible, enabling me to collect a large amount of data within each 
experiment. A dose-dependent increase of mitotic length was 
evident up to the highest dose (250 nM) when mitotic duration 
starts decreasing (Figure 19). Two additional observations were 
obtained (Figure 19): (i) multiple and dose-dependent phenotypes 
are induced, ranging from multipolar divisions to cells that re-
adhere without dividing; (ii) poor cell death induction was 
observed after MLN8237 treatment, both from mitoses and from 
the subsequent interphases. Finally, MLN8237-treated cultures 
appeared to enter more slowly in mitosis (not shown). 
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Figure 19. Effects of MLN8237 treatment on mitotic timing in high-
throughput time-lapse live cell imaging. The timing of mitosis from 
round-up to re-adhesion is shown. Each horizontal bar represents 1 cell; 
30 cells per condition are shown. Occurrence of extreme phenotypes i.e. 
cell death and re-adhesion without division are indicated by red or yellow 
rectangles at the end of the row. The experimental protocol and the color 
code (extent of Aurora kinases inhibition) are as in Figure 18. 
minutes 
Death Re-adhesion (no division) 
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To clarify effects caused by MLN8237 treatment I then analysed 
mitotic progression in dose-response assays using a medium-
throughput approach in my laboratory in Rome, in order to obtain a 
major optical and temporal resolution despite of a reduction in 
sample numerosity; parallel high resolution observations of fixed 
samples were routinely performed.  
First, I observed a reduction of cells that enter mitosis compared to 
control cultures (Figure 20). The analysis of samples fixed after 4 
hours of treatment with MLN8237 in pre-synchronised cultures 
progressing towards mitosis (Figure 20A; see protocol in Figure 
18) shows that this reduction occurs in a dose-dependent manner.  
In order to clarify whether cells were permanently arrested before 
entry into mitosis or rather delayed in progression through the 
G2/M transition, I recorded cultures from the moment of the 
treatment with the inhibitor until 16 hours later (Figure 20B). 
Time-lapse analysis confirmed a dose-dependent reduction of the 
percentage of cells that enter in mitosis within 4 hours from 
MLN8237 treatment. Still, when observing cultures during the 
subsequent 12 hours, entering of MLN8237-treated cells into 
mitosis was apparent, although strongly delayed compared to 
control cultures  (Figure 20B). 
Once in mitosis, MLN8237-treated cells are also delayed in PM 
execution (Figure 21A), recalling the prolonged duration of mitosis 
observed in the high-throughput experiments (see Figure 19); 
interestingly, though, this was consistently dose-dependent, 
including at 250 nM, a condition that in high-throughput 
experiments restored a total mitotic duration comparable more 
similar to controls. The PM delay is reflected in an accumulation 
of PM figures in fixed samples (Figure 21B), as already observed 
in previous works (Marumoto et al., 2003; De Luca et al., 2006). 
 
Together, these results show a dose-dependent delay in passing 
through the G2 to M transition and in progression through the 
mitotic division, in Aurora-A-inhibited MLN8237-treated cells. 
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Figure 20. Aurora-A inhibition by MLN8237 delays mitotic entry. A) 
Histograms represent the percentage of mitoses scored in  different 
conditions in fixed samples. At least 350 counted cells per condition, 2 
experiments. *: p < 0.01, **: p < 0.001,  χ2 test. B. The graph represents 
the percentage of interphases present at the beginning of video recording 
(at least 250 cells per condition from 3 experiments) that enter mitosis 
during the following 16 hours, under the different conditions. The 
experimental protocol and the color code (extent of Aurora kinases 
inhibition) are as in Figure 18. 
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Figure 21. Prometaphase is prolonged following Aurora-A 
inhibition. A. The time required to complete PM is indicated. Each 
symbol in the graph represents 1 cell; at least 40 cells per condition from 
3 experiments are represented. **: p < 0.001, Mann–Whitney test. B. 
Histograms represent the percentage of mitotic cells in different mitotic 
phases under the analysed conditions (at least 250 scored mitoses per 
condition, 2 experiments). Error bars denote s.d. The experimental 
protocol and the color code (extent of Aurora kinases inhibition) are as in 
Figure 18. 
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2.3. Multiple spindle defects and mitotic outcome after 
MLN8237 treatment. 
In order to clarify the reason for the delayed PM progression in 
MLN8237-treated mitoses, I analysed the effects of the treatment 
on mitotic spindle assembly and organisation. Cells that entered 
mitosis with different extent of Aurora-A or Aurora-A + Aurora-B 
inhibition displayed a variety of spindle defects (Figure 22).  
 
 
Figure 22. Mitotic spindle defects in Aurora-A-depleted cells. The IF 
panels (alpha tubulin in green, DNA in blue) show the different observed 
mitotic spindle defects. Histograms represent the percentage of mitotic 
cells displaying those abnormalities at different MLN8237 doses. Error 
bars denote s.d. 200 counted cells per condition, 2 experiments. The 
experimental protocol is as in Figure 18. Scale bar: 10 µm. 
 
Partial Aurora-A inhibition induced the formation of mitotic 
spindles with supernumerary poles and/or largely disorganised: 
interestingly, these phenotypes recalled those described following 
Aurora-A RNAi (De Luca et al., 2008; see also Figure 12 and 14), 
which indeed leaves a residual Aurora-A cellular activity 
(Marumoto et al., 2003; De Luca et al., 2006). When Aurora-A 
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activity is virtually completely inhibited, at 20 nM MLN8237 and 
higher, less than 30% of PM/M cells displayed normal spindles. 
Interestingly, a MT nucleation defect became apparent at these 
doses, which increased in a dose-dependent manner, representing 
the almost totality (about 70%) of the spindle defects at 250 nM, 
when Aurora-A and Aurora-B are concomitantly inhibited. 
To investigate how the spindle defects observed in fixed samples 
treated with MLN8237 influence cell division, I analysed mitotic 
progression and outcome by time-lapse analysis (Figure 23).  
In addition to the PM delay (Figure 21A), several phenotypes were 
observed, depending on MLN8237 dose: 
1) mis-orientation of division (Figure 23A, second row): ∼10-15% 
of mitoses divided with a normal timing, but perpendicularly 
respect to the growth surface. This determined a loss of synchrony 
at mitotic exit: one daughter cell re-adheres while the other is still 
rounded on top of it. This phenotype was observed already when 
only partial Aurora-A inhibition is achieved (5-10 nM MLN8237) 
and not when complete Aurora-A inhibition is accompanied by 
Aurora-B inactivation (50-250 nM; see Figure 18).  
2) Multipolar division (Figure 23A, third row): about 15% of 
mitoses proceed to a multipolar telophase (generally tripolar) after 
a prolonged PM, yielding division into three or more daughter cells 
with mis-segregated chromosomes. This phenotype was observed 
at all tested conditions, with prevalence in the 20 and 50 nM 
MLN8237-treated cultures.  
3) No division (Figure 23A, fourth and fifth row): an extreme 
phenotype was observed, with complete failure of division and re-
adhesion in large interphase cells from a state of PM. Sometimes 
cells re-adhere after a long PM, during which attempts to divide 
occur, with evident membrane blebs (top panels); other cells re-
adhere more rapidly without any attempt to divide (lower panels). 
This phenotype was observed with high MLN8237 doses (50-250 
nM), representing the vast majority of mitoses (>80%) at 250 nM. 
Importantly, I never observed cell death from mitosis after 
MLN8237 treatment in time-lapse analysis. 
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Figure 23. Defects during mitotic progression in Aurora-A depleted 
cells. The plate shows the different observed mitotic defects (DIC 
images); timing from mitotic onset is indicated. Histograms represent the 
percentage of mitotic cells displaying those abnormalities at different 
MLN8237 doses. Error bars denote s.d. 100 counted cells per condition, 
2 experiments. The experimental protocol is as in Figure 18. 
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In conclusion the experiments with MLN8237 in synchronously 
cycling cultures showed multiple and dose-dependent defects in 
mitotic entry, spindle assembly and mitotic progression; these are 
associated with aberrant chromosome segregation, while they do 
not significantly trigger cell death from mitosis. Importantly, 
although MLN8237 is regarded as highly specific for the Aurora-A 
kinase, my analyses call for an involvement of Aurora-B in some 
of the induced phenotypes.  
 
3. Aurora-A/TPX2 as an oncogenic holoenzyme 
As recalled in the Introduction, Aurora-A overexpression has been 
detected in many cancer types and the kinase has been proposed as 
a potential oncogene, although available data suggest that the 
specific molecular background and/or the gene profile can 
modulate the effect of Aurora-A overexpression in tumor 
progression. Aurora-A activity, localisation and stability are 
modulated by several factors; among these, the MT-binding protein 
TPX2 plays a major role in mammalian cells (see paragraphs 1.2 
and 3.2 in Introduction).  
Recent work in our laboratory, to which I contributed during my 
PhD project, identified a novel level of control of TPX2 on 
Aurora-A: TPX2 controls not only the localisation and the 
activation of the kinase but also its stability (Giubettini et al., 
2011). This evidence prompted me to investigate whether TPX2 
levels can influence the oncogenic potential of Aurora-A: high 
expression of TPX2, which would lead to abnormal activation and 
stability of Aurora-A, may contribute to modulate the transforming 
potential of Aurora-A. TPX2 overexpression may represent an 
independent route, besides Aurora-A gene amplification or 
overexpression, to increased Aurora-A levels in tumors. Besides, 
co-overexpression of the two genes may exacerbate the effect of 
Aurora-A overexpression, yielding excess amount of active 
Aurora-A/TPX2 complex, which can be more deleterious than 
overexpression of the kinase alone (Figure 24). 
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Figure 24. Scenarios for Aurora-A and TPX2 deregulation leading to 
tumorigenesis. Alterations in the Aurora-A/TPX2 complex with respect 
to a normal condition (top panel) can take place in three hypothetical 
manners: increased Aurora-A (A) or TPX2 (B) abundance, both expected 
to cause abnormal phosphorylation of Aurora-A substrates, or 
overexpression of both (C); the latter scenario yields excessive 
abundance of the whole complex, which can then act as an oncogenic 
holoenzyme. 
 
 
This hypothesis is strengthened by the evidence that both genes 
(Aurora-A and TPX2) are located on the long arm of chromosome 
20, in a region that is frequently amplied in many tumor types, 
such as breast, ovarian, cervical, colon, bladder (Knuutila et al, 
1998; Hodgson et al., 2003; Scotto et al., 2008; Beroukhim et al., 
2010): thus co-amplification of both genes can occur in cancer.  
 
To substantiate this idea I searched for evidence of TPX2 
overexpression, and TPX2/Aurora-A co-overexpression, in human 
cancer cells. 
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3.1. TPX2 is overexpressed in many tumor types. 
First, I analysed the literature for specific reports of TPX2 
overexpression in tumors. TPX2 is included in a list of more than 
50 mitotic genes with altered expression in cancer cells (Perez de 
Castro et al., 2007). Recently, by computational means, a highly 
significant correlation between TPX2 overexpression, CIN and 
cancer has been highlighted (Carter et al., 2006). Furthermore, 
several instances of TPX2 overexpression in tumor tissues and cell 
lines emerge from specific studies and in some cases this 
overexpression correlated positively with tumor grade and stage, 
with lympho-metastasis and negatively with the survival rate 
(Table 2).  
Based on the results obtained from the literature search I extended 
the analysis of TPX2 overexpression in cancer using the Oncomine 
database, a very useful tool to evaluate the expression of specific 
genes in many cancer types relative to their non-transformed tissue 
counterparts. Oncomine collects data from several datasets (484 
datasets when this analysis was performed) in which mRNA 
expression or DNA copy number were measured in primary 
tumors, cell lines or xenografts. Cancer microarray data are 
carefully reviewed before inclusion in the Oncomine database; 
computational analyses (e.g. differential expression analysis) can 
be performed and results can be filtered using specific criteria (e.g. 
tumor type, dataset type, clinical outcome and others). My search 
revealed significant TPX2 overexpression in tumors in 27% of all 
comparative analyses of tumor versus normal tissues (Table 3). 
TPX2 ranked among the first 10% or even 5% of all measured 
genes in virtually all differential expression analyses in which it 
was significantly overexpressed. Cancer types in which TPX2 
overexpression was observed include lung carcinoma, cervical 
carcinoma and sarcoma (>50% of the analyses), and head and 
neck, gastro-intestinal, kidney, liver, breast, ovarian and bladder 
cancer (between 25-50% of the analyses).	  There is a good overlap 
between cancer types extracted from the Oncomine analysis and 
those reported in specific literature studies (see Table 2).  
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Together these data suggest an oncogenic potential of TPX2,	  or an 
ability to predispose or cooperate with other genes in cell 
transformation and tumorigenesis when overexpressed. 
 
 
 
 
Table 2. TPX2 overexpression in human cancer. Studies in which 
TPX2 expression was assessed in tumor compared to normal samples are 
listed. (*) indicate studies comparing malignant vs benign, instead of 
tumor vs normal tissues. Overexpression is reported according to the 
method employed for analysis: “transcript”results were obtained from a) 
RT-PCR, b) microarrays (mRNA, cDNA), c) Northern blot, d) mRNA 
differential display or e) Reverse Northern blotting. “Protein” results 
were obtained by f) Western blot, g) immunocytochemistry, h) two-
dimensional electrophoresis.  
 
Cancer type Cell line (C) or tissue (T) 
(tumor/control) 
Overexpression 
 
Reference 
Brain T (52/5) 
               C (2/1) 
proteinf,g and transcripta 
proteinf and transcripta 
Li et al., 2010 
Oral SCCs T (43/7) transcript
a Shigeishi et al., 2009 
  T (59/10) proteinh Fenner et al., 2005 
Salivary gland T (20/6) transcriptb Shigeishi et al., 2009 
Lung 
C (31/0) 
T (31/3) transcript
a Tonon et al., 2005 
               C (1/1) 
               T (6/6) 
proteinf,g,h and transcripta 
proteinh  Zhang et al., 2008 
               C (3/4) 
  T (21/21) 
    T (595/42) 
proteinf and transcriptb 
transcripta 
proteinh 
 
Ma et al., 2006 
 
               C (9/3) transcriptc,d Manda et al., 1999 
               C (1/1) transcriptb Kadara et al., 2009 
Colon                T (1/1) transcripte Hufton et al., 1999 
Liver 
  T (10/10) transcriptb Wang et al., 2002 
 T(20/20) 
 T(64/64) 
 T(19/19) 
transcriptb 
transcripta 
proteing 
Satow et al., 2010 
Pancreas                C (9/1)   T (40/31) 
proteinf and transcripta 
proteinh Warner et al., 2009 
Ovarian    T (9/10) *                T (4/4) * 
transcriptb 
transcripta Sharer et al., 2008 
Cervix                C (9/0)   T (20/20) 
transcriptb 
transcriptb Scotto et al., 2008 
Mesothelial      T (36/22) * proteinh Taheri et al., 2008 
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Table 3: TPX2 overexpression  in tumor versus normal tissues using 
Oncomine. Oncomine™ (Compendia Bioscience) database was searched 
for TPX2 differential expression in tumor versus normal samples. The 
number and percentages of total examined analyses and cancer types in 
which TPX2 is highly significantly overexpressed (p<0.0001, Student's t-
test) are indicated. The rightmost columns show the percentages obtained 
after applying a second threshold (in addition to the p-value threshold) 
based on the gene rank, taking into account TPX2 ranking among the 
first 10%, 5% or 1% analysed genes. 
 
 
 Table II. TPX2 overexpression studies in tumor versus normal tissues  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer type 
Total 
analyses 
 (N) 
Analyses in which TPX2 is 
significantly overexpressed 
  (N)    (%)               Gene rank threshold  (%) 
   first 10% first  5% first  1% 
Brain and CNS cancer 22    5        23 18 9 0 
Head and neck cancer 13    4        31 31 23 0 
Lung cancer 13    9        69 69 69 46 
Gastrointestinal cancer 22  11        50 50 45 14 
Liver cancer  6    2        33 33 33 0 
Kidney cancer 10    3        30 20 10 10 
Pancreatic cancer   6    1        17 17 17 0 
Breast cancer   7    3        43 43 43 0 
Ovarian cancer 11    3        27 27 27 18 
Cervical cancer   1    1      100 100 100 0 
Bladder cancer   7    2        29 14 14 14 
Prostate cancer 14    0          0 0 0 0 
Lymphoma 11    0          0 0 0 0 
Leukemia 12    1          8 8 0 0 
Myeloma   2    0          0 0 0 0 
Sarcoma   8    6        75 75 75 63 
Melanoma   6    0          0 0 0 0 
Other cancer 22    2          9 9 9 5 
Total 193   53       27 26 23 10 
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3.2. Aurora-A and TPX2 coexpression in tumors 
The simultaneous overexpression of both TPX2 and Aurora-A can 
determine a particularly relevant situation in which the high 
abundance of Aurora-A protein would find non-limiting amounts 
of its activator TPX2: under these conditions, the Aurora-A/TPX2 
complex would yield abnormal phosphorylation of downstream 
targets. Concomitant overexpression of Aurora-A and TPX2 could 
therefore confer a proliferative advantage over normal cells and 
promote tumor growth (see Figure 24). 
I found direct evidence in the literature for Aurora-A and TPX2 
coexpression in tumors. Aurora-A is included in the cancer-
associated chromosomal instability CIN70 signature, in which 
TPX2 ranks first, identified in the computational study previously 
mentioned (Carter et al., 2006). In addition, overexpression of both 
Aurora-A and TPX2 has been shown in a study on lung cancer, 
comparing cancer vs normal lung cells, and was also detected in 
samples from carcinoma vs adenoma ovarian cancer patients in a 
combination of genome-wide expression data, in silico interaction 
network analysis and real time PCR mRNA measurements 
(Scharer et al, 2008; Kadara et al., 2009). 
To assess the general validity of these observations, I again 
screened the Oncomine database (Table 4). First, I noticed that in 
around 70% of the analyses in which TPX2 was significantly 
overexpressed, Aurora-A was overexpressed as well.	   Then I used 
the Oncomine coexpression analysis tool, which assigns 
correlation values (cv) to all genes in a dataset with respect to a 
gene of interest (cv = 1 indicates genes that are co-overexpressed ). 
I used Aurora-A and TPX2 as references genes (see Materials and 
Methods for details): Aurora-A cvs with respect to TPX2 were 
>0.5 in 19 out of 22 datasets; cvs were remarkably high (≥ 0.8) in 
12 out of 22 datasets, indicating that Aurora-A and TPX2 are 
expressed with a similar pattern. In the reciprocal analysis, setting 
Aurora-A as the “reference gene” and examining TPX2 
coexpression, cvs were >0.5 in 16/20 and ≥0.8 in 11/20 datasets. 
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Table 4: Co-overexpression of TPX2 and Aurora-A in cancer. 
Coexpression of Aurora-A (AurkA) and TPX2 was evaluated using 
Oncomine by (i) correlation values (see 
https://www.oncomine.org/content/org/help/OncomineHelpFile.htm for 
how these values are calculated; 1 indicates a perfect positive 
correlation), and (ii) position of Aurora-A in the list of TPX2 
coexpressed genes and viceversa (position 1 is the most coexpressed 
gene). In each analysis, only datasets in which the reference gene was 
significantly and frequently overexpressed (as explained in detail in the 
Materials and Methods) were considered; n.i. (not included) indicates 
datasets excluded in one or the other analysis due to these criteria. TCGA 
(The Cancer Genome Atlas): Ovarian Serous Cystadenocarcinoma Gene 
Expression Data. Note that controls (non tumor) in each analysis are 
often less numerous than tumor samples. 
Detwiller et al., 2005 15/39 
 
 
Cancer 
type 
    
 Coexpression with TPX2        Coexpression with AurkA  
AurkA 
correlation     
value  
AurkA  
gene 
position  
 
TPX2 
correlation      
value  
TPX2 
gene 
position  
N control/ 
N tumor 
Data- set 
legend 
Head and 
neck 
0.84 
0.86 
  5 
  2 
 0.84 
0.86 
  6 
  2 
12/26 
13/41 
Ye et al., 2008 
Ginos et al., 2004 
Lung 
0.74 
0.88 
0.78 
0.84 
0.58 
n.i. 
17 
  1 
        105 
44 
32 
         n.i. 
 0.74 
0.88 
0.78 
0.84 
0.58 
      <0.44 
27 
  1 
        105 
 23 
 27 
      >400 
6/67 
19/20 
31/35 
49/58 
17/186 
5/5 
Garber et al., 2001 
Stearman et al., 2005 
Su et al., 2007 
Landi et al., 2008 
Bhattacharjee et al., 2001 
Wachi et al., 2005 
Gastro-
intestinal 
      <0.46 
0.86 
      <0.15 
0.81 
0.95 
      <0.36 
      >400 
  2 
      >400 
  6 
        238 
      >400 
       <0.38 
0.86 
      <0.44 
0.81 
0.95 
      <0.14 
      >400 
   3 
      >400 
   5 
        221 
     >400 
41/82 
5/100 
22/56 
12/48 
94/94 
29/103 
Ki et al., 2007 
Kaiser et al., 2007 
Gaspar et al., 2008 
Graudens et al., 2006 
Kurashina et al., 2008 
Chen et al., 2003 
Liver 0.80         128  0.80 21 10/65 Wurmbach et al., 2007 
Kidney 0.66 0.85 
      >400 
15 
 n.i. 
n.i. 
n.i. 
n.i. 
10/10 
11/59 
Gumz et al., 2007 
Beroukhim et al., 2009 
Breast 0.86 0.64 
32 
        101 
 0.86 
0.64 
22 
94 
7/40 
3/61 
Richardson et al., 2006 
Zhao et al., 2004 
Ovarian 0.70 0.87 
43 
23 
 n.i. 
n.i. 
n.i. 
n.i. 
5/45 
10/38 
Lu et al., 2004 
TCGA 
Bladder 0.83 11  0.83 10 48/109 Sanchez et al., 2006 
Prostate n.i. n.i.  0.81  4 23/89 Yu et al., 2004 
Sarcoma 0.73 75  0.7382 15/39          
    82 
82  
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Since cvs may be influenced by the overall background noise 
within a dataset, we also used a second parameter to evaluate 
coexpression, i.e. Aurora-A position among TPX2-coexpressed 
genes and viceversa. We found that in 13 out of 22 datasets 
Aurora-A was among the first 50 TPX2-coexpressed genes (of at 
least 6000 measured genes), while TPX2 ranked among the first 50 
Aurora-A coexpressed genes in 12/20 analyses, again indicating a 
positive correlation between Aurora-A and TPX2 overexpression 
in tumors (see Table 4). 
To control for the specificity of the co-overexpression I assessed 
coexpression of TPX2 with two additional mitotic genes, Aurora-B 
(which is highly similar to Aurora-A in sequence, but acts in a 
different pathway) and the unrelated Plk1 kinase.	   Neither gene 
displayed good coexpression with TPX2: cvs were ≥ 0.8 in 3 out of 
22 datasets for Plk1 and in 2 out 22 for Aurora-B; furthermore, 
Aurora-B and Plk1 were within the first 50 TPX2 coexpressed 
genes in only 3 and 6 datasets, respectively (not shown).	  	  
These data reinforce the idea that the Aurora-A/TPX2 complex 
may act as a novel functional unit, or “holoenzyme”, with specific 
consequences in cell transformation and tumorigenesis. 
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DISCUSSION  
 
My PhD thesis focused on the Aurora-A kinase, with the aim to 
clarify its mechanisms of action in mitosis and the effects of its 
deregulation on cell division, also with respect to its possible 
involvement in cancer. 
Results obtained in my PhD project indicate that Aurora-A is 
needed for establishing a finely-tuned balance among MT-
associated forces operating in bipolar spindle formation. I observed 
that in Aurora-A defective cells an imbalance among MT forces 
directed towards centrosomes determines the fragmentation of 
mitotic spindle poles: 
- Aurora-A-defective mitoses display hyperstable MTs associated 
with spindle pole fragmentation; the co-inactivation of ch-TOG, a 
MT-stabiliser, rescues spindle pole fragmentation as shown in 
previous work (De Luca et al., 2008), but also counteracts the 
abnormal MT hyperstabilisation caused by Aurora-A inactivation. 
- Inhibition of the kinesin Eg5 reduces the occurrence of the 
spindle pole fragmentation phenotype induced by Aurora-A 
depletion. 
- Reduction of spindle extrapoles is also evident in Aurora-A-
inactivated cells after silencing of the KT protein Nuf2, a condition 
in which MT-KT attachments are destabilised. 
The evidence that loss of activity of ch-TOG, Eg5 and Nuf2 
prevents Aurora-Ai-dependent pole abnormalities, despite of their 
otherwise divergent biological functions, strengthens the idea that 
the rescuing activity is associated with their shared property to 
modulate pole-directed forces. I schematised these data in a model 
(Figure 25) in which I show how Aurora-A interplays with forces 
regulating spindle pole formation. It is conceivable that in Aurora-
A-defective cells the pressure directed towards poles is excessive, 
or is not properly counteracted at the centrosome, and spindle poles 
fragment.  
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Figure 25.  Aurora-A modulates the balance of forces required for 
spindle pole integrity: a model. Upper panel: in a normal mitosis 
balanced MT forces determine the formation of a symmetrical bipolar 
spindle. Arrows represent opposite-directed MT forces. Central panel: in 
Aurora-A-defective mitoses, spindles display fragmented poles. Lower 
panel: pole disruption is prevented by either inactivating a MT stabiliser 
(ch-TOG), or weakening KT-generated (Nuf2 silencing), or inhibiting 
(monastrol) Eg5-associated centrosome-directed MT forces in the 
absence of Aurora-A activity. The model suggests therefore that spindle 
poles fragment consequently to the imbalance in MT-generated forces in 
Aurora-A-defective mitoses. 
Spindle  with !
fragmented poles in!
Aurora-A inactivated cells!
Bipolar spindle!
Aurora-A inactivation!
MT hyperstabilisation!
Spindle force imbalance!
Rescued spindle bipolarity!
(resistant to cold induced depolymerisation)!
Further inactivation of !
MT-interacting factors!
ch-Tog RNAi!
(MT-stabiliser)!
!
Nuf2 RNAi!
(MT/kinetochore!
 stabilising factor)!
Eg5 kinesin!
(monastrol)!
balanced MT forces!
imbalanced MT forces!
pericentrin!
α-tubulin!
DAPI!
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ch-TOG and Aurora-A are part of a complex in human cells 
(Fielding et al., 2008) and in Xenopus extracts (Koffa et al., 2006). 
In Xenopus the complex also contains Eg5 that is a substrate of 
Aurora-A (Koffa et al., 2006; Giet et al., 1999). Therefore it is 
possible that Aurora-A regulates Eg5, and possibly ch-TOG, by 
modulating their interactions, and, in the case of Eg5, its 
phosphorylation status. The rescue obtained with Aurora-A/Nuf2 
co-depletion does not necessarily imply a direct link between 
Aurora-A and the KT protein Nuf2, but is more likely to reflect a 
global re-balancing of MT forces in Aurora-A-defective cells 
following the destabilisation of MT-KT attachments, adding 
support to the notion that K-fibers directly contribute to spindle 
pole organisation (Manning and Compton, 2007; Toso et al., 
2009). 
The present data suggest that investigating the status of spindle 
forces in Aurora-A-overexpressing cells may be relevant for 
understanding the mechanisms of the Aurora-A transforming 
ability; at the same time they raise a concern that Aurora-A 
inhibitors, currently under evaluation in anti-cancer therapy, may 
facilitate the formation of multipolar spindles and hence 
chromosome segregation defects. The extent of chromosome mis-
segregation may determine opposite outcomes: on the one hand, 
mild aneuploidy facilitates tumorigenesis; on the other hand, 
massive aneuploidy generated by strong mis-segregation defects 
yields cell death and it is therefore regarded as a potential strategy 
to kill cancer cells (see Figures 5 and 6 in Introduction). 
In order to investigate the cellular effects of Aurora-A inhibition 
by chemical compounds used in clinical trials, I used the 
MLN8237 inhibitor in human cells. High-resolution and 
quantitative microscopy with fixed samples, as well as medium- 
and high-throughput time-lapse observations enabled me to obtain 
information at single cell level. The combination of these 
approaches has enabled me to gain insight both in potential novel 
mitotic functions of Aurora-A and in the cellular response to 
Aurora-A inhibition, and together have underlined the importance 
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of accompanying cellular analyses to clinically directed 
investigations.  
 
MLN8237 is considered the most specific inhibitor of Aurora-A 
that has arrived to phase II evaluation in clinical trials. The dose-
response assays that I have performed indicate partial specificity of 
action of MLN8237, when used in cultured cells, on Aurora-A vs 
Aurora-B: 20 nM MLN8237 is the only tested condition with 
virtually complete Aurora-A inhibition and unaltered Aurora-B 
activity. Partial Aurora-B inhibition observed at 50 nM MLN8237 
is less evident with the widely used anti-phospho-Ser10-Histone 
H3 marker of Aurora-B activity (not shown), maybe reflecting 
kinase redundancy or a differential sensitivity of auto-
phosphorylation vs targets phosphorylation; this may represent a 
reason for not having detected this partial specificity of action in 
previous studies (Sloane et al., 2010; Manfredi et al., 2011).  
Spindle abnormalities and mis-aligned chromosomes have been 
described following MLN8237 treatment (Manfredi et al., 2011), 
although the majority of the studies carried out with this inhibitor 
are clinical. I characterised in depth mitotic entry and progression 
in the presence of different MLN8237 concentrations. Dose-
response assays enabled me to assess processes that are more 
robust in respect to Aurora kinases inhibition, compared to others 
which on the contrary are quickly affected. 
I first confirmed that Aurora-A inhibition impairs entry into 
mitosis, that was previously observed by either antibody 
microinjection (Marumoto et al., 2002) or RNAi in synchronised 
cultures (Hirota et al., 2003). This was under-appreciated in 
experiments performed in asynchronous cultures (Sloane et al., 
2010; Manfredi et al., 2011), but may be relevant for the use of 
Aurora-A inhibition in cancer therapy: indeed, G2 arrest is 
transient, thus not impairing cell division; in addition, non-
physiological  divisions may follow this “pausing” period, during 
which alterations may accumulate.  
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Phenotypes previously described using RNAi or chemical 
inhibitors were reproduced, i.e PM delay, spindles displaying 
additional poles or disorganised spindles (Marumoto et al., 2003; 
De Luca et al., 2006 and 2008). In addition, novel phenotypes were 
apparent: 
1) cells totally devoid of MTs,  that only display spots of tubulin or 
little asters, that I regarded as a MT nucleation defect; this may 
well relate to the proposed function of Aurora-A in centrosome 
maturation. It remains to be clarified whether the occurrence of this 
phenotype at the highest doses of MLN8237 is dependent on a 
more complete inhibition of Aurora-A activity under these 
conditions, or on the contribution of Aurora-B which is also 
inhibited at those doses; indeed, no evidence so far supports the 
involvement of Aurora-B in MT nucleation. 
2) As soon as Aurora-A is partially inhibited, many cells perform a 
mis-oriented division, perpendicular to the growth surface; this can 
reflect a role of Aurora-A in the orientation of mitotic spindle 
and/or an involvement in regulating cell adhesion to the substrate. 
Interestingly, Aurora-A was shown to contribute to spindle 
orientation in Drosophila S2 cells and neuroblasts (Johnston et al., 
2009; Yamada et al., 2010).  
3) Finally, by time-lapse imaging I observed the absence of 
chromosome segregation and the re-adhesion into one single cell at 
high concentrations of MLN8237 inhibitor. Similar defects have 
been described with the Aurora-A inhibitor MLN8054 
(Chakravarty et al., 2010; Sloane et al., 2010). It is known that 
Aurora-B inhibition is dominant on Aurora-A inhibition, given its 
effects on mitotic checkpoint overcoming and failure of 
cytokinesis (Yang et al., 2005); in addition, a similar defect in cell 
division was described in chicken cells as typical of Aurora-A+B 
inactivation (Hégarat et al., 2011). Together with my finding on the 
partial aspecificty of MLN8237 (see above), these observations 
suggest that this extreme phenotype is dependent on the 
concomitant inhibiton of the two kinases.  
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In cell cultures experiments, cells are continually exposed to a 
constant concentration of anti-mitotic agents, while the 
concentration of the drug in vivo will vary. The majority of anti-
mitotic agents are administered intravenously, and therapies are 
based on cyclic treatment of only a few hours, on a weekly basis: 
thus, drug concentration increases, peaks and falls and exposure of 
the tumor to an effective dose is likely to be transient (Gascoigne 
and Taylor, 2008). Thus, the large spectrum of mitotic phenotypes, 
mirroring the dose-dependent inhibition levels of Aurora kinases, 
observed in my experiments in cultured cells, may all contribute to 
the response in patients, and hence have relevant consequences for 
the outcome of therapies.  
The dose-dependency of mitotic outcomes may also be highly 
relevant for therapy. I never observed death from mitosis, which is 
the desirable outcome of an anti-mitotic treatment: chemical 
compounds that act specifically in mitosis determine alterations in 
mitotic progression and, if cells do not die, chromosome mis-
segregation and generation of aneuploid daughter cells is likely to 
occur. If the aneuploidy is not massive, but compatible with the 
cell survival, cells will go through different cell cycles with high 
probability to accumulate defects and mutations that can drive 
tumorigenesis. Indeed, a preliminary analysis of interphase cells 
originating from MLN8237-treated mitoses reveals that these cells 
accumulate DNA abnormalities in a dose-dependent manner 
(Figure 26): at 20 nM cells have normal nuclei and display only a 
low percentage (10% of cells) of chromosome loss or gain, 
comparable to control cultures.  Treatment with 50 nM MLN8237 
yields binucleated or polyploid cells (40%) and multinucleated 
cells (23%). Together, these results indicate that increasing 
MLN8237 concentration does not induce mitotic death, but rather 
the accumulation of DNA abnormalities in the subsequent 
interphases.  The collaboration with the ALMF of the EMBL of 
Heidelberg will give me the opportunity to use high-throughput 
microscopy and to perform analysis of the data with automated 
methods (using softwares such as CellCognition): this will be for 
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me an essential support to measure the influence of multiple 
parameters on the effects of Aurora-A inhibition on cell division, 
in particular with respect to cell death induction, and identify cell 
types where intervention by Aurora-A inhibition may be effective. 
 
 
 
 
Figure 26. Outcome of mitoses treated with the MLN8237 inhibitor. 
The IF panels show the different scored categories. DNA is in blue, α-
tubulin is in red, pericentrin, used to identify the presence of multiple 
centrosomes (indicative of failed division) is in green. Histograms 
represent the percentage of interphases, under two different MLN8237 
dose conditions, in the classes shown in the IF panels. At least 100 
counted cells per condition, 1 preliminary experiment, **: p < 0.001, χ2 
test. Scale Bar: 10 µm 
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linked to the role of its overexpression in tumorigenesis: 
specifically, I addressed the possibility that the oncogenic potential 
of Aurora-A can be modulated by altered levels of its 
interactors/regulators. I focussed on TPX2, that is the major 
regulator of Aurora-A, and hypothesised that its overexpression 
may be relevant to elicit Aurora-A transforming potential.  
Data discussed in chapter 3 of the Results suggest that elevated 
TPX2 levels provide an additional route to increased Aurora-A 
activity in cells.  By a search in the literature and using the 
Oncomine database it was evident that TPX2 is overexpressed in 
many tumor types; more, the co-overexpression of Aurora-A and 
TPX2 has emerged as a feature of many tumors. TPX2 
overexpression alone in cultured cells mainly induces the 
appearance of monopolar spindles associated with mitotic arrest, 
and induction of apoptosis has also been reported (Gruss et al., 
2002; Stewart and Fang, 2005). These phenotypes can hardly 
support completion of an abnormal cell division that would then 
give rise to viable genetically imbalanced cells. These observations 
suggest that concomitant mitotic defects, such as a concomitant 
weakening of the mitotic checkpoint for example, can contribute to 
cell transformation. The simultaneous overexpression of both 
TPX2 and Aurora-A can indeed determine a particularly relevant 
situation; in that case the high abundance of Aurora-A protein, 
which is critical for proper exit from mitosis (Meraldi et al., 2002), 
would be accompanied by high levels of its activator TPX2. 
Consequently, spindle formation and function and balanced 
chromosome segregation would be deregulated, and aneuploid 
daughter cells can be originated. The concomitant overexpression 
of Aurora-A and TPX2 could therefore confer a proliferative 
advantage over normal cells and favor tumor growth. A recent 
study supports this hypothesis. Aurora-A and TPX2 are both on the 
q arm of the chromosome 20, which is frequently amplified in 
cancer; Sillars-Hardebol and collaborators analysed several 
colorectal carcinoma and adenoma, and identified TPX2 and 
AURKA as two genes on the 20q amplicon important to promote 
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colorectal adenoma to carcinoma progression. They also show that 
down-modulation of TPX2 and Aurora-A inhibits invasion (Sillars-
Hardebol, 2011).  
The observation that Aurora-A and TPX2 are frequently co-
overexpressed, together with our recent finding that TPX2, besides 
its ability to up regulate the kinase activity, also regulates Aurora-
A protein stability (Giubettini et al., 2011), suggest that protein 
stabilisation, even in the absence of gene amplification, represents 
an additional route to Aurora-A increased levels in cancer. 
Growing evidence correlate abnormal Aurora-A protein stability to 
tumors and are consistent with this view: 
(i) increased Aurora-A protein levels, without amplification or 
overexpression of the gene, have been reported in head and neck 
cancers (Kitajima et al., 2007), and are associated with abnormal 
phosphorylation on Ser51, a modification that protects Aurora-A 
from degradation (Crane et al., 2004); 
(ii) the Aurora-A allelic variants associated with increased risk of 
cancer  involve amino acids 31 and 57, both of which lie in the 
proximity of the A-box degradation motif, and may therefore 
render the A-box less accessible or less effective, again suggesting 
a possible contribution of Aurora-A stabilisation to tumorigenesis. 
 
Based on my observations that current Aurora-A inhibitors display 
critical specificity issues, associated with aneuploidy induction, 
and that the Aurora-A/TPX2 complex may act as an oncogenic 
unit, I would like to propose that the Aurora-A/TPX2 complex may 
also represent a potential target in cancer therapy. Recent TPX2 
inactivation experiments have yielded anti-proliferative effects in 
cancer cells (Morgan-Lappe et al., 2007; Zhang et al., 2008; 
Warner et al., 2009; Li et al., 2010; Satow et al., 2010), suggesting 
a potential value of TPX2 as an anti-cancer target; the 
effectiveness of TPX2 inactivation or downregulation may reflect, 
at least in part, the ensuing down-regulation of the Aurora-A/TPX2 
holoenzyme. Direct approaches to develop specific inhibitors of 
the Aurora-A/TPX2 complex formation, which would not be active 
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against the related kinase Aurora-B, may constitute a novel 
strategy in the field of Aurora-A targeting in cancer therapy.  
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MATERIALS AND METHODS 
 
Cell cultures, synchronisation protocols and treatments 
U2OS cells (ATCC: HTB-96) were cultured at 37 oC in a 5% CO2 
atmosphere in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum, 2% L-glutamine, 2% 
penicillin/streptomycin. For synchronisation, cells were subjected 
to a 24 hours treatment with 2 mM thymidine. Cultures were then 
released from the G1/S arrest by washing away the thymidine (3 
washes with DMEM for 5 minutes at 37 oC) and adding fresh 
medium containing 30 µM deoxycytidine to restore the synthesis 
of deoxyribonucleotide triphosphates; about 10 hours post-release, 
mitoses-enriched cultures were fixed and processed for IF, WB or 
video recorded. MLN8237 (5-250 nM, as indicated; Selleck 
Chemicals), NOC (0,1 µg/ml) and MON (100 µΜ) were added to 
thymidine-released cultures at the indicated times before 
harvesting. When indicated, asynchronously growing cultures were 
treated with MON for 6 hours; after 3 washes with DMEM as 
above, cultures were released in complete medium for 30 and 60 
minutes. For MT depolymerisation experiments, cells were 
incubated on ice for 10, 15 and 20 minutes, then fixed and 
processed for IF. 
 
RNAi 
cDNA sequences targeted by small interfering (si)RNA 
oligonucleotides (QIAGEN or Applied Biosystems/Ambion) are: 
725- ATGCCCTGTCTTACTGTCA-743 (Aurora-A), 126- 
GAGCCCAGAGTGGTCCAAA-144 (ch-TOG), 397-
GCATGCCGTGAAACGTATA-415 (Nuf2). A GL2 siRNA 
duplex targeting the luciferase gene was used for control. Final 
concentrations of siRNA oligonucleotides were: 80 nM (Aurora-A 
and GL2), 40 nM (ch-TOG) and 60 nM (Nuf2). In co-transfections 
of Aurora-A and either ch-TOG or Nuf2 siRNAs the final amount 
of siRNA oligonucleotides in control cultures was balanced (to 120 
or 140 nM, respectively) by adding GL2 oligo. Transfection 
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reagent was Oligofectamine (Invitrogen). Cultures were analysed 
48 hours after transfection. Experiments were repeated 2 to 4 
times; statistical analysis of data was performed using the χ2 test 
and calculating standard deviations (s.d.), as indicated.  
 
IF 
Cells grown on coverslips were fixed as follows: (a) -20°C 
methanol, 6 minutes; (b) 3,7% PFA plus 0.2% TritonX-100 in 20 
mM Pipes pH 6.9, 1 mM MgCl2, 10 mM EGTA, 10 minutes at 
room temperature; or c) fixed in 3.7% PFA (10’) and then 
permeabilised in 0.1% Triton-X100–PBS1X (5’). Blocking and all 
antibody incubations were performed at room temperature in PBS 
containing 0.05% Tween 20 and 3% BSA. Cells were 
counterstained with 4,6-diamidino-2-phenylindole (DAPI, 0.05 
µg/ml) and mounted using Vectashield Mounting Medium (Vector 
MLaboratories) that prevents rapid photobleaching of several 
fluorophores. Primary antibodies were: anti-alpha-tubulin (1:2000, 
B-5-1-2, Sigma), anti-Aurora-A (0.5 µg/ml, BD Transduction 
Laboratories), anti-phospho-Aurora-A (Thr288) (1:250; C39D8; 
Cell Signaling Technology), anti-pericentrin (2 µg/ml, ab4448; 
Abcam), anti-ch-TOG (1:25, ab18320, Abcam), anti-Nuf2 (1:300, 
ab17058; Abcam), anti phospho-Aurora-B (Thr232) (1:50; 
Poly6361 BioLegend); anti phospho-Histone H3 (Ser10) (0,25 
µg/ml; 3H10; Millipore). 
Fixed samples were analysed using a Nikon Eclipse 90i 
microscope equipped with a Qicam Fast 1394 CCD camera 
(Qimaging). An oil immersion 100X (N.A. 1.3) objective was 
used. Image acquisition was performed using NIS-Elements AR 
3.2 (Nikon); three-dimensional deconvolution of the 0.4-µm or 0.6-
µm Z-serial optical sections and reconstruction was performed 
using the “Legacy” or “AutoQuant” deconvolution modules of 
Nis-Elements AR 3.2/4.0. Creation of image projections from z-
stacks was also performed using the Maximum Intensity Projection 
(for quantitative analyses), and Extended Depth of Focus functions 
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of NIS-Elements AR 3.2/4.0. Images were processed also with 
Adobe Photoshop CS 6.0.  
Signals were measured using NIS Elements AR 3.2/4.0 (nd2 file 
format), using the “manual measurements” function: external 
background correction was applied and the sum intensity of signals 
on indicated selected area was measured. Values were statistically 
analysed using the InStat3 software, using either (i) the unpaired 
Student’s t-test (for Gaussian distributions), applying the Welch 
correction when required, or (ii) the Mann–Whitney test, when the 
populations did not follow a Gaussian distribution. 
 
Time-lapse live cell imaging 
Cells were seeded in wells/dishes with glass bottom or with bottom 
made of 0,18 mm microscopy plastic with highest optical quality 
(both from Ibidi) and cultured as described above. Cultures were 
video recorded from the moment of treatment (6 hours after 
thymidine release) for the indicated times. The microscope was a 
Nikon Ti Eclipse automated inverted microscope, equipped with a 
water jacket CO2 stage incubator (Okolab), designed to mantain 
cultures under controlled environmental conditions right on the 
microscope stage. Before imaging, medium was replaced with 
DMEM without Phenol Red. Acquisition was performed without 
lids to optimise image quality and anti-evaporation oil (Ibidi) was 
added on top of the medium in order to avoid evaporation. Image 
acquisition was performed using a DS-Qi1MC (Nikon) camera and 
the software NIS-Elements AR 3.2 (Nikon) at 5 minutes intervals 
for 16 or 24 hours. Plan Fuor 40x (N.A. 0,60) and Plan Apo 60x 
(oil, N.A. 1,3) objectives were used and acquisitions were 
performed using differential interference contrast (DIC).  
At the Advanced Light Microscopy Facility of Heidelberg, cells 
were seeded in 96-well dishes with glass surface. Images were 
acquired every 30 minutes for 48-65 hours with a 10x objective 
using an Olympus Cell^R Scan^R automated microscope with 
EMBL Environment box to control environmental conditions 
(http://www.embl.de/almf/almf_services/booking/micro_olympus_
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scan/index.html). Hoechst (1:1000, Sigma) was added for 1 hour 
prior to video recording (and then removed), in order to stain 
DNA. Transmitted light and fluorescence images were acquired. 
Videos were mounted and analysed using Fiji (an image processing 
package of ImageJ) and NIS-Elements AR 4.0 (Nikon). 
Preliminary analyses were also performed using the software 
CecogAnalyzer (http://cellcognition.org). 
 
WB 
Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1% NP40, 1 mM EGTA, 0.25% sodium deoxycholate) 
supplemented with protease and phosphatase inhibitors. Proteins 
were resolved by electrophoresis on 10% Laemmli gel and 
transferred on a nitrocellulose membrane (Protran BA83, 
Whatman) using a semi-dry system (BIO-RAD). 30 µg of extract 
per lane were loaded. Blocking and antibody incubations were 
performed at room temperature in TBS containing 0.1% Tween-20 
and 5% low fat milk. Antibodies were: anti-Aurora-A (0.5 µg/ml), 
anti-Nuf2 (1:1 000, kind gift of V. Draviam), anti-phospho-Aurora-
A (Thr288) (1:500; C39D8; Cell Signaling Technology), anti-actin 
(0.5 µg/ml, I-19; SantaCruz Biotechnology). Signals were 
visualised by enhanced chemiluminescence detection (ECL plus, 
GE Healthcare, and Protein Detection System, GeneSpin). 
 
Oncomine™ (Compendia Bioscience) analyses 
TPX2 overexpression studies were perfomed using the 
Oncomine™ database (www.oncomine.org), searching for TPX2 
differential expression in tumor versus normal samples. A first 
threshold was set for highly significant overexpression (p<0.0001, 
Student's t-test); a second threshold was based on the gene rank, 
taking into account TPX2 ranking among the first 10%, 5% or 1% 
overexpressed genes in each analysis. 
Co-expression analyses of Aurora-A and TPX2 were also 
performed. In each analysis, only datasets in which the reference 
gene was highly significantly (p<0.0001) and frequently 
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overexpressed were considered. Datasets include 6000–20000 
genes. Datasets from tissues in which overexpression occurred in 
less than 25% (TPX2) or 20% (Aurora-A) of all examined cases, or 
containing data from non homogeneous tissues, were not 
considered. 
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